def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
þ |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
o |
|
Soliciting Material Pursuant to §240.14a-12 |
THERMO FISHER SCIENTIFIC INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its
filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
|
81 Wyman Street
Waltham, MA 02451
April 8,
2010
Dear Stockholder:
You are cordially invited to attend the 2010 Annual Meeting of
Stockholders of Thermo Fisher Scientific Inc., which will be
held on Wednesday, May 26, 2010, at 1:30 p.m. (Eastern
time) at the Mandarin Oriental New York, 80 Columbus Circle at
60th Street, New York, New York.
The notice of meeting and proxy statement accompanying this
letter describe the specific business to be acted upon at the
meeting. The Companys 2009 Annual Report to Stockholders
also accompanies this letter.
It is important that your shares of the Companys common
stock be represented and voted at the meeting regardless of the
number of shares you may hold. Whether or not you plan to attend
the meeting in person, you can ensure your shares of the
Companys common stock are voted at the meeting by
submitting your instructions by telephone, the Internet, or in
writing by returning the Companys proxy card (if one has
been provided to you). Please review the instructions in the
enclosed proxy statement and proxy card regarding each of these
voting options.
We are pleased this year to again take advantage of the
Securities and Exchange Commission rule allowing companies to
furnish proxy materials to their stockholders over the Internet.
We believe that this
e-proxy
process expedites stockholders receipt of proxy materials,
while lowering the costs and reducing the environmental impact
of our annual meeting. Stockholders receiving
e-proxy
materials have been sent a notice containing instructions on how
to access the proxy statement and annual report over the
Internet and how to vote.
Thank you for your continued support of the Company.
Yours very truly,
MARC N. CASPER
President and Chief Executive Officer
81 Wyman Street
Waltham, MA 02451
NOTICE OF 2010 ANNUAL MEETING
OF STOCKHOLDERS
To be
held on May 26, 2010
Important
Notice Regarding the Availability of Proxy Materials for the
Annual Meeting of Stockholders to be Held on May 26,
2010.
The Proxy Statement and 2009 Annual Report are available at
www.proxyvote.com.
April 8,
2010
To the
Holders of the Common Stock of
THERMO FISHER SCIENTIFIC INC.
Notice is hereby given that the 2010 Annual Meeting of
Stockholders of Thermo Fisher Scientific (Thermo
Fisher or the Company) will be held on
Wednesday, May 26, 2010, at 1:30 p.m. (Eastern time)
at the Mandarin Oriental New York, 80 Columbus Circle at
60th Street, New York, New York.
The purpose of the meeting is to consider and take action upon
the following matters:
|
|
|
|
1.
|
Election of two directors for a three-year term expiring in 2013.
|
|
|
2.
|
Ratification of the Audit Committees selection of
PricewaterhouseCoopers LLP as the Companys independent
auditors for 2010.
|
|
|
3.
|
Such other business as may properly be brought before the
meeting and any adjournment thereof.
|
Stockholders of record at the close of business on
March 29, 2010, are the only stockholders entitled to
notice of and to vote at the 2010 Annual Meeting of Stockholders.
This notice, the proxy statement and the proxy card enclosed
herewith are sent to you by order of the Board of Directors of
the Company.
By Order of the Board of Directors,
SETH H. HOOGASIAN
Senior Vice President, General Counsel and Secretary
IMPORTANT
Whether or not you intend to attend the meeting in person,
please ensure that your shares of the Companys common
stock are present and voted at the meeting by submitting your
instructions by telephone, the Internet, or in writing by
completing, signing, dating and returning the enclosed proxy
card to our tabulation agent in the enclosed, self-addressed
envelope, which requires no postage if mailed in the United
States.
Directions to the Annual Meeting are available by calling
Investor Relations at
(781) 622-1111.
Table
of Contents
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
8
|
|
|
|
|
9
|
|
|
|
|
10
|
|
|
|
|
10
|
|
|
|
|
11
|
|
|
|
|
11
|
|
|
|
|
11
|
|
|
|
|
11
|
|
|
|
|
21
|
|
|
|
|
22
|
|
|
|
|
24
|
|
|
|
|
26
|
|
|
|
|
29
|
|
|
|
|
29
|
|
|
|
|
30
|
|
|
|
|
33
|
|
|
|
|
42
|
|
|
|
|
42
|
|
|
|
|
42
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
44
|
|
|
|
|
45
|
|
|
|
|
46
|
|
|
|
|
46
|
|
|
|
|
47
|
|
|
|
|
48
|
|
|
|
|
48
|
|
|
|
|
49
|
|
|
|
|
49
|
|
|
|
|
50
|
|
|
|
|
51
|
|
|
|
|
52
|
|
|
|
|
53
|
|
|
|
|
53
|
|
|
|
|
53
|
|
|
|
|
54
|
|
|
|
|
54
|
|
|
|
|
54
|
|
|
|
|
55
|
|
|
|
|
55
|
|
81 Wyman Street
Waltham, MA 02451
PROXY
STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS
May 26,
2010
This proxy statement is furnished in connection with the
solicitation of proxies by Thermo Fisher Scientific Inc.
(Thermo Fisher or the Company) on behalf
of the Board of Directors of the Company (the Board)
for use at the 2010 Annual Meeting of Stockholders to be held on
Wednesday, May 26, 2010, at 1:30 p.m. (Eastern time)
at the Mandarin Oriental New York, 80 Columbus Circle at
60th Street, New York, New York, and any adjournments
thereof. The mailing address of the principal executive office
of the Company is 81 Wyman Street, Waltham, Massachusetts 02451.
This proxy statement and enclosed proxy card are being first
furnished to stockholders of the Company on or about
April 12, 2010.
Purpose
of Annual Meeting
At the 2010 Annual Meeting of Stockholders, stockholders
entitled to vote at the meeting will consider and act upon the
matters outlined in the notice of meeting accompanying this
proxy statement, including the election of two directors for a
three-year term expiring in 2013, and the ratification of the
selection of PricewaterhouseCoopers LLP as the Companys
independent auditors for 2010.
Voting
Securities and Record Date
Only stockholders of record at the close of business on
March 29, 2010, the record date for the meeting, are
entitled to vote at the meeting or any adjournments thereof. At
the close of business on March 29, 2010, the outstanding
voting securities of the Company consisted of
410,364,690 shares of the Companys common stock, par
value $1.00 per share (Common Stock). Each share of
Common Stock outstanding at the close of business on the record
date is entitled to one vote on each matter that is voted.
Quorum
The presence at the meeting, in person or by proxy, of a
majority of the outstanding shares of Common Stock entitled to
vote at the meeting will constitute a quorum for the transaction
of business at the meeting. Votes of stockholders of record
present at the meeting in person or by proxy, abstentions, and
broker non-votes (as defined below) are counted as
present or represented at the meeting for the purpose of
determining whether a quorum exists. A broker
non-vote occurs when a broker or representative does not
vote on a particular matter because it either does not have
discretionary voting authority on that matter or it does not
exercise its discretionary voting authority on that matter.
Manner of
Voting
Stockholders
of Record
Shares entitled to be voted at the meeting can only be voted if
the stockholder of record of such shares is present at the
meeting, returns a signed proxy card, or authorizes proxies to
vote his or her shares by telephone or over the Internet. Shares
represented by valid proxy will be voted in accordance with your
instructions. If you choose to vote your shares by telephone or
over the Internet, which you may do until 11:59 p.m.
Eastern time on Tuesday, May 25, 2010, you should follow
the instructions provided on the proxy card. In voting by
telephone or over the Internet, you will be allowed to confirm
that your instructions have been properly recorded.
A stockholder of record who votes his or her shares by telephone
or Internet, or who returns a proxy card, may revoke the proxy
at any time before the stockholders shares are voted at
the meeting by entering new votes by telephone or over the
Internet by 11:59 p.m. Eastern time on May 25, 2010,
by written notice to
Page 2
the Secretary of the Company received prior to the meeting, by
executing and returning a later dated proxy card prior to the
meeting, or by voting by ballot at the meeting.
Participants
in the Thermo Fisher Scientific 401(k) Retirement Plan and the
Fisher Hamilton L.L.C. Retirement Savings Plan
If you hold your shares through the Thermo Fisher Scientific
401(k) Retirement Plan or the Fisher Hamilton L.L.C. Retirement
Savings Plan (each, a 401(k) Plan), your proxy
represents the number of shares in your 401(k) Plan account as
of the record date. For those shares in your 401(k) Plan
account, your proxy will serve as voting instructions for the
trustee of the 401(k) Plan. You may submit your voting
instructions by returning a signed and dated proxy card to the
Companys tabulation agent in the enclosed, self-addressed
envelope for its receipt by 11:59 p.m. Eastern time on
Friday, May 21, 2010, or by telephone or over the Internet
by 11:59 p.m. Eastern time on Sunday, May 23, 2010, in
accordance with the instructions provided on the proxy card.
You may revoke your instructions by executing and returning a
later dated proxy card to the Companys tabulation agent
for its receipt by 11:59 p.m. Eastern time on May 21,
2010, or by entering new instructions by telephone or over the
Internet by 11:59 p.m. Eastern time on May 23, 2010.
Beneficial
Stockholders
If you hold your shares through a broker, bank or other
representative (broker or representative), you can
only vote your shares in the manner prescribed by the broker or
representative. Detailed instructions from your broker or
representative will generally be included with your proxy
material. These instructions may also include information on
whether your shares can be voted by telephone or over the
Internet or the manner in which you may revoke your votes. If
you choose to vote your shares by telephone or over the
Internet, you should follow the instructions provided by the
broker or representative.
Voting of
Proxies
Shares represented by proxy will be voted in accordance with
your specific choices. If you sign and return your proxy card or
vote by telephone or over the Internet without indicating
specific choices, your shares will be voted FOR the nominees for
director and FOR the ratification of the selection of
independent auditors for 2010. Should any other matter be
properly presented at the meeting, the persons named in the
proxy card will vote on such matter in accordance with their
judgment.
If you sign and return your proxy card marked
abstain on the proposal regarding the election of
directors or the proposal to ratify the selection of independent
auditors for 2010 or choose the same option when voting by
telephone or over the Internet, your shares will not be voted
affirmatively or negatively on those proposals and will not be
counted as votes cast with regard to those proposals.
If you hold your shares as a beneficial owner rather than a
stockholder of record, your broker or representative will vote
the shares that it holds for you in accordance with your
instructions (if timely received) or, in the absence of such
instructions, your broker or representative may vote on certain
matters for which it has discretionary voting authority,
including the proposal to ratify the selection of independent
auditors for 2010. Please note that as a result of recent
amendments to stock exchange rules, brokers or representatives
subject to those rules no longer have discretionary voting
authority with respect to uncontested elections of directors.
Therefore, if you do not instruct your broker or representative
regarding how you would like your shares to be voted, your
broker or representative will not be able to vote on your behalf
with respect to the election of directors.
If you hold your shares through the 401(k) Plan, the trustee
will vote the shares in your 401(k) Plan account in accordance
with your instructions (if timely received) or, in the absence
of such instructions, the Company will vote your shares FOR the
nominees for director and FOR the ratification of the selection
of independent auditors for 2010.
Page 3
Vote
Required for Approval
Under the Companys bylaws, in an uncontested election, a
nominee for director will be required to obtain a majority of
the votes cast in person or by proxy at the annual meeting in
order to be elected, such that the number of votes cast
for a director must exceed the number of votes cast
against that director. Abstentions and broker
non-votes will not have an effect on the determination of
whether a nominee for director has been elected.
Under the Companys bylaws, approval of the proposal to
ratify the selection of independent auditors for 2010 will
require the affirmative vote of a majority of the shares present
or represented and entitled to vote at the annual meeting and
voting affirmatively or negatively on the matter. Abstentions
and broker non-votes will not have an effect on the
determination of whether stockholder approval of the matter has
been obtained.
-
PROPOSAL 1 -
ELECTION
OF DIRECTORS
The number of directors constituting the full Board is currently
fixed at twelve. Effective as of the date of this years
Annual Meeting of Stockholders, the number of directors will be
fixed at eleven. The Board is divided into three classes, and
each class is elected for a three-year term at successive
Annual Meetings of Stockholders. In all cases, directors hold
office until their successors have been elected and qualified,
or until their earlier resignation, death or removal.
The terms for Marc N. Casper, Michael A. Bell, Stephen P.
Kaufman and Tyler Jacks expire at the 2010 Annual Meeting of
Stockholders. Each of Messrs. Kaufman and Bell has informed
the Company of his decision to not stand for re-election as
director at the meeting. The Nominating and Corporate Governance
Committee of the Board has recommended to the Board, and the
Board has nominated, Messrs. Casper and Jacks for a
three-year term expiring at the 2013 Annual Meeting of
Stockholders. Proxies may not be voted for a greater number of
persons than the two nominees named. The Board has commenced a
search to fill the vacancy that will exist following the 2010
Annual Meeting of Stockholders. The Board intends to fill that
vacancy by Board action once a new director candidate is
identified.
Nominees
and Incumbent Directors
Set forth below are the names of the persons nominated as
directors and directors whose terms do not expire this year,
their ages, their offices in the Company, if any, their
principal occupations or employment for the past five years, the
length of their tenure as directors and the names of other
public companies in which they currently hold directorships or
have held directorships during the past five years. We have also
presented information below regarding each directors
specific experience, qualifications, attributes and skills that
led our Board to the conclusion that he or she should serve as a
director. Information regarding their beneficial ownership of
Common Stock is reported under the heading SECURITY
OWNERSHIP.
Page 4
Nominees
for Director Whose Term of Office Will Expire in 2013
|
|
|
|
|
|
|
|
Marc N. Casper
Mr. Casper, age 42, has been a director of the Company since October 2009. He has been President and Chief Executive Officer of the Company since October 2009. He served as the Companys Chief Operating Officer from May 2008 to October 2009 and was Executive Vice President from November 2006 to October 2009. Prior to being named Executive Vice President, he was Senior Vice President from December 2003 to November 2006. Prior to joining the Company, Mr. Casper served as president, chief executive officer and a director of Kendro Laboratory Products. Mr. Casper is also a director of Zimmer Holdings, Inc. and within the last five years was a director of The Advisory Board Company. We believe that Mr. Casper is well suited to serve on our Board due to his position as Chief Executive Officer of the Company as well as his 13 years in the life sciences/healthcare equipment industry.
|
|
|
|
|
|
Tyler Jacks
Dr. Jacks, age 49, has been a director of the Company since May 2009. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT) and director of the David H. Koch Institute for Integrative Cancer Research. He joined the MIT faculty in 1992 and was director of its Center for Cancer Research from 2001 to 2008. Since 2002, Dr. Jacks has been an investigator with the Howard Hughes Medical Institute. We believe that Dr. Jacks is well suited to serve on our Board due to his experience as a cancer researcher and member of multiple scientific advisory boards in biotechnology companies, pharmaceutical companies and academic institutions.
|
Incumbent
Directors Whose Term of Office Will Expire in 2011
|
|
|
|
|
|
|
|
Thomas J. Lynch
Mr. Lynch, age 55, has been a director of the Company since May 2009. He is Chief Executive Officer of Tyco Electronics Ltd., a global provider of engineered electronic components, network solutions, undersea telecommunication systems and specialty products. He joined Tyco International in 2004 as President of Tyco Engineered Products and Services and was appointed to his current position in January 2006, when Tyco Electronics became an independent, separately traded entity. Mr. Lynch is also a director of Tyco Electronics Ltd. We believe that Mr. Lynch is well suited to serve on our Board due to his experience as Chief Executive Officer of a comparably-sized global company.
|
|
|
|
|
|
William G. Parrett
Mr. Parrett, age 64, has been a director of the Company since June 2008. Until his retirement in May 2007, he served as Chief Executive Officer of Deloitte Touche Tohmatsu, a global accounting firm. Mr. Parrett joined Deloitte in 1967, and served in a series of roles of increasing responsibility. Mr. Parrett serves as a director of the Blackstone Group LP and chairman of its Audit Committee. He is also a director of Eastman Kodak Company and UBS AG. We believe that Mr. Parrett is well suited to serve on our Board due to his experience as Chief Executive Officer of Deloitte Touche Tohmatsu, which demonstrates his leadership capability and extensive knowledge of complex financial and operational issues.
|
Page 5
|
|
|
|
|
|
|
|
Michael E. Porter
Dr. Porter, age 62, has been a director of the Company since July 2001. He has been the Bishop William Lawrence University Professor at Harvard University since December 2000 and was C. Roland Christensen Professor of Business Administration from 1990 to 2000. Dr. Porter is a leading authority on competitive strategy and international competitiveness. Dr. Porter is also a director of Parametric Technology Corporation. We believe that Dr. Porter is well suited to serve on our Board due to his expertise in corporate strategy development and organizational acumen.
|
|
|
|
|
|
Scott M. Sperling
Mr. Sperling, age 52, has been a director of the Company since November 2006. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from January 1998 to November 2006. He has been employed by Thomas H. Lee Partners, L.P., a leveraged buyout firm, and its predecessor, Thomas H. Lee Company, since 1994. Mr. Sperling currently serves as Co-President of Thomas H. Lee Partners, L.P. Mr. Sperling is also a director of Warner Music Group Corp. and CC Media Holdings, Inc., and within the last five years was a director of Wyndham International, Inc., Houghton Mifflin Company, Univision Communications Inc., and Vertis, Inc. We believe that Mr. Sperling is well suited to serve on our Board due to his experience in acquisitions and finance.
|
Incumbent
Directors Whose Term of Office Will Expire in 2012
|
|
|
|
|
|
|
|
Judy C. Lewent
Ms. Lewent, age 61, has been a director of the Company since May 2008. She was Chief Financial Officer of Merck & Co., Inc., a global pharmaceutical company, from 1990 until her retirement in 2007. She was also Executive Vice President of Merck from February 2001 through her retirement and had additional responsibilities as President, Human Health Asia from January 2003 until July 2005, when she assumed strategic planning responsibilities for Merck. Ms. Lewent is also a director of Dell, Inc. and Motorola, Inc. We believe that Ms. Lewent is well suited to serve on our Board due to her many years of global experience in finance and the pharmaceutical industry.
|
|
|
|
|
|
Peter J. Manning
Mr. Manning, age 71, has been a director of the Company since May 2003. He served as Vice Chairman, Strategic Business Development of FleetBoston Financial Corporation from October 1999 to February 2003 when he retired. From January 1993 to October 1999, Mr. Manning served as Executive Director, Mergers & Acquisitions of BankBoston Corporation, prior to its acquisition by FleetBoston Financial. From 1990 to 1993, he served as Executive Vice President and Chief Financial Officer of BankBoston Corporation. Mr. Manning also serves as a director of Safety Insurance Group Inc. and chairman of its Audit Committee. We believe that Mr. Manning is well suited to serve on our Board due to his many years of experience in finance and accounting.
|
Page 6
|
|
|
|
|
|
|
|
Jim P. Manzi
Mr. Manzi, age 58, has been a director of the Company since May 2000 and Chairman of the Board since May 2007. He was also Chairman of the Board from January 2004 to November 2006. He has been the Chairman of Stonegate Capital, a firm he formed to manage private equity investment activities in technology startup ventures, primarily related to the Internet, since 1995. From 1984 until 1995, he served as the Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. We believe that Mr. Manzi is well suited to serve on our Board due to his senior management experience leading Lotus and overall business acumen.
|
|
|
|
|
|
Elaine S. Ullian
Ms. Ullian, age 62, has been a director of the Company since July 2001. She was the President and Chief Executive Officer of Boston Medical Center, a 550-bed academic medical center affiliated with Boston University, from July 1996 to her retirement in January 2010. Ms. Ullian is also a director of Vertex Pharmaceuticals, Inc. and Hologic Inc., and within the last five years was a director of Valeant Pharmaceuticals International. We believe that Ms. Ullian is well suited to serve on our Board due to her experience as Chief Executive Officer of Boston Medical Center, a healthcare provider similar to many of the Companys customers.
|
The Board of Directors recommends a vote FOR the
nominees for director. Proxies solicited by the Board of
Directors will be voted FOR the nominees unless stockholders
specify to the contrary on their proxy.
Directors
Whose Terms will Expire at the 2010 Annual Meeting
Michael
A. Bell
Mr. Bell, age 54, has been a director of the Company
since July 2007 and has been Managing Partner of Monitor Clipper
Partners, a private equity firm, since January 1998. He also
served as Senior Executive Vice President of John Hancock
Financial Services from October 2001 to April 2004.
Stephen
P. Kaufman
Mr. Kaufman, age 68, has been a director of the
Company since July 2007 and a Senior Lecturer of Business
Administration at the Harvard Business School since January
2001. He is retired Chairman and Chief Executive Officer of
Arrow Electronics, Inc., a distributor of semiconductors,
peripherals and components. He became President and Chief
Operating Officer of Arrow in 1985, Chief Executive Officer in
1986, and Chairman in 1994. He retired as Chief Executive
Officer in June 2000 and reassumed that position in June 2002 on
an interim basis until September 2002. Mr. Kaufman is also
a director of Harris Corporation and KLA-Tencor Corporation.
Page 7
CORPORATE
GOVERNANCE PRINCIPLES AND BOARD MATTERS
The Board has adopted governance principles and guidelines of
the Company (Corporate Governance Guidelines)
to assist the Board in exercising its duties and to best serve
the interests of the Company and its stockholders. In addition,
the Company has adopted a code of business conduct and ethics
(Code of Business Conduct and Ethics) that
encompasses the requirements of the rules and regulations of the
Securities and Exchange Commission (SEC) for a
code of ethics applicable to principal executive
officers, principal financial officers, principal accounting
officers or controllers, or persons performing similar
functions. The Code of Business Conduct and Ethics
applies to all of the Companys officers, directors and
employees. The Company intends to satisfy SEC and New York Stock
Exchange (NYSE) disclosure requirements regarding
amendments to, or waivers of, the Code of Business Conduct
and Ethics by posting such information on the Companys
website. The Companys Corporate Governance Guidelines
and Code of Business Conduct and Ethics are available
on its website at www.thermofisher.com. We may also use our
website to make certain disclosures required by the rules of the
NYSE, including the following:
the identity of the
presiding director at meetings of non-management or independent
directors;
|
|
|
|
|
the method for interested parties to communicate directly with
the presiding director or with non-management or independent
directors as a group;
|
|
|
|
the identity of any member of the issuers audit committee
who also serves on the audit committees of more than three
public companies and a determination by the Board that such
simultaneous service will not impair the ability of such member
to effectively serve on the Companys audit
committee; and
|
|
|
|
contributions by the Company to a tax exempt organization in
which any non-management or independent director serves as an
executive officer if, within the preceding three years,
contributions in any single fiscal year exceeded the greater of
$1 million or 2% of such tax exempt organizations
consolidated gross revenues.
|
Director
Nomination Process
The Nominating and Corporate Governance Committee considers
recommendations for director nominees suggested by its members,
other directors, management and other interested parties. It
will consider stockholder recommendations for director nominees
that are sent to the Nominating and Corporate Governance
Committee to the attention of the Companys Secretary at
the principal executive office of the Company. In addition, the
bylaws of the Company set forth the process for stockholders to
nominate directors for election at an annual meeting of
stockholders.
The process for evaluating prospective nominees for director,
including candidates recommended by stockholders, includes
meetings from time to time to evaluate biographical information
and background material relating to prospective nominees,
interviews of selected candidates by members of the Nominating
and Corporate Governance Committee and other members of the
Board, and application of the Companys general criteria
for director nominees set forth in the Companys
Corporate Governance Guidelines. These criteria include
the prospective nominees integrity, business acumen, age,
experience, commitment, and diligence. Our Corporate Governance
Guidelines specify that the value of diversity on the Board
should be considered by the Nominating and Corporate Governance
Committee in the director identification and nomination process.
The Nominating and Corporate Governance Committee does not
assign specific weights to particular criteria and no particular
criterion is necessarily applicable to all prospective nominees.
The Committee believes that the backgrounds and qualifications
of the directors considered as a group should provide a
significant breadth of experience, knowledge and abilities to
assist the Board in fulfilling its responsibilities. The
Nominating and Corporate Governance Committee also considers
such other relevant factors as it deems appropriate, including
the current composition of the Board, the balance of management
and independent directors, and, with respect to members of the
Audit Committee, financial expertise.
After completing its evaluation, the Nominating and Corporate
Governance Committee makes a recommendation to the full Board as
to the persons who should be nominated by the Board, and the
Board
Page 8
determines the nominees after considering the recommendation and
report of the Nominating and Corporate Governance Committee.
Since 2008, the Nominating and Corporate Governance Committee
has engaged Egon Zehnder International, a search firm, to
facilitate the identification, screening and evaluation of
qualified, independent candidates for director to serve on the
Board. Dr. Jacks, who is a nominee for election by the
Companys stockholders for the first time, and
Mr. Lynch, both of whom were elected to the Board in 2009,
were recommended to the Board by Egon Zehnder.
Director
Independence
The Companys Corporate Governance Guidelines
require a majority of our Board to be
independent within the meaning of the NYSE listing
requirements including, in the judgment of the Board, the
requirement that such directors have no material relationship
with the Company (either directly or as a partner, shareholder
or officer of an organization that has a relationship with the
Company). The Board has adopted the following standards to
assist it in determining whether a director has a material
relationship with the Company. Under these standards, a director
will not be considered to have a material relationship with the
Company if he or she is not:
A director who is a current
employee, or whose immediate family member is a current
executive officer, of a company that has made payments to, or
received payments from, the Company for property or services in
an amount which, in any of the last three fiscal years, exceeds
the greater of $1 million, or 2% of such other
companys consolidated gross revenues;
A director who is (or was
within the last three years) an employee, or whose immediate
family member is (or was within the last three years) an
executive officer, of the Company;
A director who has received,
or whose immediate family member has received, during any
twelve-month period within the last three years, more than
$120,000 in direct compensation from the Company, other than
director and committee fees and pension or other forms of
deferred compensation for prior service (provided such
compensation is not contingent in any way on continued service);
(A) A director who is,
or whose immediate family member is, a current partner of a firm
that is the Companys internal or external auditor;
(B) a director who is a current employee of a firm that is
the Companys internal or external auditor; (C) a
director whose immediate family member is a current employee of
a firm that is the Companys internal or external auditor
and personally works on the Companys audit; or (D) a
director who was, or whose immediate family member was, within
the last three years (but is no longer) a partner or employee of
a firm that is the Companys internal or external auditor
and personally worked on the Companys audit within that
time;
A director who is (or was
within the last three years), or whose immediate family member
is (or was within the last three years), an executive officer of
another company where any of the Companys current
executive officers at the same time serve or served on the other
companys compensation committee;
A director who is (or was
within the last three years) an executive officer of another
company that is indebted to the Company, or to which the Company
is indebted, in an amount that exceeds one percent (1%) of the
total consolidated assets of the other company; and
A director who is a current
executive officer of a tax exempt organization that, within the
last three years, received discretionary contributions from the
Company in an amount that, in any single fiscal year, exceeded
the greater of $1 million or 2% of such tax exempt
organizations consolidated gross revenues. (Any automatic
matching by the Company of employee charitable contributions
will not be included in the amount of the Companys
contributions for this purpose.)
Ownership of a significant amount of the Companys stock,
by itself, does not constitute a material relationship. For
relationships not covered by these standards, the determination
of whether a material relationship exists shall be made by the
other members of the Board who are independent (as defined
above).
Page 9
The Board has determined that each of Mses. Lewent and Ullian,
Messrs. Bell, Kaufman, Lynch, Manning, Manzi, Parrett and
Sperling, and Drs. Jacks and Porter is
independent in accordance with the Companys
Corporate Governance Guidelines and Section 303A.02
of the listing standards of the NYSE. Each of Mses. Lewent and
Ullian, Messrs. Kaufman, Lynch, Manning, Manzi, Parrett and
Sperling, and Dr. Porter has no relationship with the
Company, other than any relationship that is categorically not
material under the guidelines shown above and other than
compensation for services as a director as disclosed in this
proxy statement under DIRECTOR COMPENSATION.
Dr. Jacks is a professor at the Massachusetts Institute of
Technology (MIT), and is the director of the David
H. Koch Institute for Integrative Cancer Research at MIT. He is
also an employee of and investigator for the Howard Hughes
Medical Institute (HHMI). MIT and HHMI purchase
certain products and services from the Company in the ordinary
course of business. Dr. Jacks is not a partner of,
controlling shareholder in, or executive officer of either MIT
or HHMI. The independent directors (other than Dr. Jacks)
determined that neither Dr. Jacks position at MIT,
nor his employment by HHMI, is material to his independence as a
director of the Company. The independent directors (other than
Mr. Bell) also determined that Mr. Bells
relationship with Monitor Clipper Partners, a private equity
firm that manages two funds in which a Company pension plan is
an investor, is not material to his independence as a director
of the Company (see Transactions with Related
Persons on page 49).
Board of
Directors Meetings and Committees
The Board met nine times during 2009. During 2009, each of our
directors attended at least 75% of the total number of meetings
of the Board and the committees of which such director was a
member. The Board has a standing Audit Committee, Compensation
Committee and Nominating and Corporate Governance Committee. The
Company encourages, but does not require, the members of its
Board to attend the annual meeting of stockholders. Last year,
five of our directors attended the 2009 Annual Meeting of
Stockholders.
Audit
Committee
The Audit Committee is responsible for assisting the Board in
its oversight of the integrity of the Companys financial
statements, the Companys compliance with legal and
regulatory requirements, the independent auditors
qualifications and independence, and the performance of the
Companys internal audit function and independent auditors.
Certain responsibilities of our Audit Committee and its
activities during fiscal 2009 are described with more
specificity in the Report of the Audit Committee in this proxy
statement under the heading REPORT OF THE AUDIT
COMMITTEE. The charter of the Audit Committee is available
on the Companys website at www.thermofisher.com.
The current members of our Audit Committee are
Messrs. Parrett (Chairman), Lynch and Manning. The Board
has determined that each of the members of the Audit Committee
is independent within the meaning of SEC rules and
regulations, the listing standards of the NYSE, and the
Companys Corporate Governance Guidelines, and that
each is financially literate as is required by the
listing standards of the NYSE. The Board has also determined
that each of Messrs. Parrett and Manning qualifies as an
audit committee financial expert within the meaning
of SEC rules and regulations, and that they each have accounting
and related financial management expertise as is required by the
listing standards of the NYSE. The Board has determined that
Mr. Parretts membership on four audit committees does
not impair his ability to effectively serve on the
Companys Audit Committee. The Audit Committee met 12 times
during 2009.
Compensation
Committee
The Compensation Committee is responsible for reviewing and
approving compensation matters with respect to the
Companys chief executive officer and its other officers,
reviewing and recommending to the Board management succession
plans, and administering equity-based plans. Certain
responsibilities of our Compensation Committee and its
activities during 2009 are described in this proxy statement
under the heading Compensation Discussion and
Analysis. The Compensation Committee also periodically
reviews our director compensation, and makes recommendations on
this topic to the Board as it deems appropriate, as described
under the heading DIRECTOR COMPENSATION. The charter
of the Compensation Committee is available on the Companys
website at www.thermofisher.com.
Page 10
The current members of our Compensation Committee are
Messrs. Sperling (Chairman), Jacks and Lynch and
Ms. Ullian. The Board has determined that each of the
members of the Compensation Committee is independent
within the meaning of the listing standards of the NYSE and the
Companys Corporate Governance Guidelines. The
Compensation Committee met 13 times during 2009.
Role of
Consultant
The Compensation Committee has sole authority to retain and
terminate a compensation consultant to assist in the evaluation
of CEO or senior executive compensation. Since October 2007, the
Committee has retained Pearl Meyer & Partners
(PM&P) as its independent compensation
consultant. PM&P does not provide any other services to the
Company.
The consultant compiles information regarding the components and
mix (short-term/long-term; fixed/variable; cash/equity) of the
executive compensation programs of the Company and its peer
groups (see page 13 of this proxy statement for further
detail regarding the peer groups), analyzes the relative
performance of the Company and the peer groups with respect to
the financial metrics used in the programs, and provides advice
to the Compensation Committee regarding the Companys
programs. The consultant also provides information regarding
emerging trends and best practices in executive compensation.
The consultant retained by the Compensation Committee reports to
the Compensation Committee Chair and has direct access to
Committee members. The consultant periodically attends Committee
meetings either in person or by telephone, and meets with the
Committee in executive session without management present.
Nominating
and Corporate Governance Committee
The Nominating and Corporate Governance Committee is responsible
for identifying persons qualified to serve as members of the
Board, recommending to the Board persons to be nominated by the
Board for election as directors at the annual meeting of
stockholders and persons to be elected by the Board to fill any
vacancies, and recommending to the Board the directors to be
appointed to each of its committees. In addition, the Nominating
and Corporate Governance Committee is responsible for developing
and recommending to the Board a set of corporate governance
guidelines applicable to the Company (as well as reviewing and
reassessing the adequacy of such guidelines as it deems
appropriate from time to time) and overseeing the annual
self-evaluation of the Board. The charter of the Nominating and
Corporate Governance Committee is available on the
Companys website at www.thermofisher.com.
The current members of our Nominating and Corporate Governance
Committee are Dr. Porter (Chairman) and Messrs. Bell,
Lynch and Sperling. The Board has determined that each of the
members of the Nominating and Corporate Governance Committee is
independent within the meaning of the listing
standards of the NYSE and the Companys Corporate
Governance Guidelines. The Nominating and Corporate
Governance Committee met six times during 2009.
Board
Leadership Structure
We separate the roles of Chief Executive Officer and Chairman of
the Board in recognition of the differences between the two
roles. The CEO is responsible for setting the strategic
direction for the Company and the day to day leadership and
performance of the Company, while the Chairman of the Board
provides guidance to the CEO and sets the agenda for Board
meetings and presides over meetings of the Board.
Our
Boards Role in Risk Oversight
Our Board oversees our risk management processes directly and
through its committees. Our management is responsible for risk
management on a
day-to-day
basis. The role of our Board and its committees is to oversee
the risk management activities of management. The Audit
Committee assists the board in fulfilling its oversight
responsibilities with respect to risk management in the areas of
financial reporting, internal controls and compliance with legal
and regulatory requirements, and, in accordance with NYSE
requirements, discusses policies with respect to risk assessment
and risk management, including guidelines and policies to govern
the
Page 11
process by which the Companys exposure to risk is handled.
Risk assessment reports are periodically provided by management
to the Audit Committee. The Compensation Committee assists the
Board in fulfilling its oversight responsibilities with respect
to the management of risks arising from our compensation
policies and programs. The Nominating and Corporate Governance
Committee assists the Board in fulfilling its oversight
responsibilities with respect to the management of risks
associated with board organization, membership and structure,
succession planning for our directors, and corporate governance.
Executive
Sessions
In accordance with the listing standards of the NYSE and the
Companys Corporate Governance Guidelines,
independent directors meet at least twice a year in an executive
session without management and at such other times as may be
requested by any independent director. Through February 2009,
Ms. Ullian served as presiding director at the meetings of
the Companys independent directors held in executive
session without management. Effective February 26, 2009,
Jim P. Manzi, as the Chairman of the Board, was chosen to
preside at the meetings of the Companys independent
directors held in executive session without management.
Communications
from Stockholders and Other Interested Parties
The Board has established a process for stockholders and other
interested parties to send communications to the Board or any
individual director or groups of directors, including the
Chairman of the Board and the independent directors.
Stockholders and other interested parties who desire to send
communications to the Board or any individual director or groups
of directors should write to the Board or such individual
director or group of directors care of the Companys
Corporate Secretary, Thermo Fisher Scientific Inc., 81 Wyman
Street, Waltham, Massachusetts 02451. The Corporate Secretary
will relay all such communications to the Board, or individual
director or group of directors, as the case may be.
EXECUTIVE
COMPENSATION
Compensation
Discussion and Analysis
The Compensation Committee oversees our executive compensation
program for officers. In this role, the Compensation Committee
reviews and approves annually all compensation decisions
relating to our named executive officers. Our named executive
officers for the year ended December 31, 2009 are Marc N.
Casper, President and Chief Executive Officer, Peter M. Wilver,
Senior Vice President and Chief Financial Officer, Gregory J.
Herrema, Senior Vice President, Alan J. Malus, Senior Vice
President, Edward A. Pesicka, Senior Vice President, and Marijn
E. Dekkers, Former President and Chief Executive Officer.
Objectives
and Philosophy of Our Executive Compensation Program
The primary objectives of our executive compensation program are
to:
attract and retain the best
possible executive talent;
ensure executive
compensation is aligned with our corporate strategies and
business objectives;
promote the achievement of
key strategic and financial performance measures by linking
annual cash incentives to the achievement of corporate
performance goals;
motivate the Companys
officers in creating long-term value for the Companys
stockholders and achieving other business objectives of the
Company; and
encourage stock ownership by
the Companys officers in order to align their financial
interests with the long-term interests of the Companys
stockholders.
To achieve these objectives, the Compensation Committee
evaluates our compensation program for officers with the goal of
setting compensation at levels the Committee believes are
competitive with those of
Page 12
other peer companies that compete with us for executive talent.
In addition, our executive compensation program ties a
substantial portion of each executives overall cash
compensation to key strategic, financial and operational goals
such as revenue growth, margin expansion, and new product
introductions. We also provide a portion of our executive
compensation in the form of stock options, restricted stock and
restricted stock unit grants (both time-based and
performance-based), which we believe helps to retain our
executives and aligns their interests with those of our
stockholders by allowing them to participate in the longer term
success of the Company as reflected in stock price.
The Compensation Committee uses market surveys and analyses
prepared by outside consulting firms to stay informed of
developments in the design of compensation packages generally
and to benchmark our officer compensation program against those
of companies with whom we compete for executive talent to ensure
our compensation program is in line with current marketplace
standards. The Compensation Committee generally targets
compensation for executives near (e.g., within 10%) the median
of the pay levels derived from the compensation
consultants studies. Variations to this general target may
occur as dictated by individual circumstances.
Typically, during the first calendar quarter of each year, the
chief executive officer makes a recommendation to the
Compensation Committee with respect to annual salary increases
and bonuses, and annual stock option and restricted stock
awards, if any, for executive officers other than himself, which
is then reviewed and approved by the Compensation Committee. The
Compensation Committee annually reviews the individual
performance evaluations for the named executive officers, and,
usually in February, determines their compensation changes and
awards after receiving input from the independent directors of
the Board. As part of this process, the Compensation Committee
also reviews, with respect to each named executive officer, the
current value of prior equity grants, the balances in deferred
compensation accounts, and the amount of compensation the
executive officer would receive if he left the Company under a
variety of circumstances.
Components
of our Executive Compensation Program
The primary elements of our executive compensation program are:
|
|
|
|
Element
|
|
|
Primary Purpose
|
Base Salary
|
|
|
Provide competitive, fixed compensation to attract and retain
the best possible executive talent
|
Annual Cash Incentive Bonuses
|
|
|
Align executive compensation with our corporate strategies and
business objectives; promote the achievement of key strategic
and financial performance measures by linking annual cash
incentives to the achievement of corporate performance goals
|
Stock Option, Restricted Stock and Restricted Stock Unit Awards
|
|
|
Align executive compensation with our corporate strategies and
business objectives; motivate the Companys officers in
creating long-term value for the Companys stockholders and
achieving other business objectives of the Company; encourage
stock ownership by the Companys officers in order to align
their financial interests with the long-term interests of the
Companys stockholders
|
Insurance, Retirement and Other Employee Benefits
|
|
|
Provide competitive benefits to attract and retain the best
possible executive talent
|
Severance and Change in Control Benefits
|
|
|
Provide competitive benefits to attract and retain the best
possible executive talent and facilitate the executives
evaluating potential business combinations
|
|
|
|
|
We do not have any formal or informal policy or target for
allocating compensation between cash and non-cash compensation
or among the different forms of non-cash compensation. Instead,
the Compensation Committee, after reviewing information provided
by compensation consultants, determines what it believes in its
business judgment to be the appropriate level of each of the
various compensation components.
Page 13
The Committee believes that the Companys executive
compensation program supports the executive compensation
objectives described above without encouraging management to
take unreasonable risk with respect to Thermo Fishers
business. The Committee believes that the programs use of
long-term, equity based compensation, the use of both options
and restricted stock awards, and our stock ownership guidelines
all encourage management to take a long-term view of Thermo
Fishers performance and discourage unreasonable
risk-taking. The Committee has reviewed our key compensation
policies and practices and concluded that any risks arising from
our policies and programs are not reasonably likely to have a
material adverse effect on the Company.
In late 2007, the Committee directly engaged Pearl
Meyer & Partners (PM&P), a
compensation consulting firm, to assist the Committee in its
review and evaluation of the compensation for the executive
officers. PM&P provides no services to the Company other
than to the Compensation Committee, and is therefore entirely
independent of the management of the Company. In making
decisions on 2009 salary changes, the setting of 2009 target
annual cash incentive bonuses as a percentage of salary, and
equity award decisions in February 2009, the Committee
considered the market study prepared by PM&P in late 2007,
which included data from three peer groups (the core peer group,
the broader industry peer group, and the small competitors peer
group) of publicly-traded companies as well as industry survey
data for other companies that were deemed relevant by PM&P.
PM&P did not consult with management in developing its peer
groups or in providing its analysis to the Compensation
Committee. The core peer group represents companies most similar
to Thermo Fisher in terms of size and industry. The companies
included in the core peer group at that time were:
|
|
|
Agilent Technologies Inc.
|
|
Baxter International Inc.
|
Becton, Dickinson and Company
|
|
Boston Scientific Corporation
|
Danaher Corporation
|
|
Quest Diagnostics Incorporated
|
Rockwell Automation, Inc.
|
|
Medtronic, Inc.
|
Stryker Corporation
|
|
|
The broader industry peer group represented companies that were
of similar size as compared to Thermo Fisher and that compete in
broader, but related, industries. The broader industry peer
group consisted of:
|
|
|
Abbott Laboratories
|
|
Avaya Inc.
|
Cooper Industries, Ltd.
|
|
Dover Corporation
|
Eaton Corporation
|
|
EMC Corporation
|
Emerson Electric Co.
|
|
Goodrich Corporation
|
Harris Corporation
|
|
Illinois Tool Works Inc.
|
ITT Corporation
|
|
Parker-Hannifin Corporation
|
Precision Castparts Corp.
|
|
Raytheon Company
|
Rockwell Collins, Inc.
|
|
Schering-Plough Corporation (now part of Merck & Co., Inc.)
|
The small competitors peer group represented companies that were
similar to Thermo Fisher in product or service offerings, but
had annual revenues less than one-third that of Thermo Fisher.
The small competitors peer group consisted of:
|
|
|
Applera Corporation Applied Biosystems
|
|
Invitrogen Corporation (now part of Life
|
(now part of Life Technologies Corporation)
|
|
Technologies Corporation)
|
Beckman Coulter, Inc.
|
|
PerkinElmer, Inc.
|
Millipore Corporation
|
|
Tektronix, Inc. (now part of Danaher Corporation)
|
Roper Industries, Inc.
|
|
Waters Corporation
|
Varian, Inc.
|
|
|
C.R. Bard, Inc.
|
|
|
PM&P employed regression analysis techniques in order to
examine the relationship between company revenue size and pay,
and used that relationship to calculate predicted pay values for
a company of Thermo Fishers size. For Messrs. Wilver
and Dekkers, PM&P used a blend of size-regressed peer group
data and size-regressed industry survey data. For
Mr. Casper (in the Chief Operating Officer position),
PM&P used size-regressed broader industry peer group data
only, due to an inadequate sample size in core peer companies.
For
Page 14
Mr. Malus, and the positions currently held by
Messrs. Herrema and Pesicka, PM&P used size-regressed
peer group data only, because for these operational positions,
PM&P deemed the core peer group data more relevant than
broader industry survey data that would represent a wider range
of businesses.
Base
Salary
Base salary is used to recognize the experience, skills,
knowledge and responsibilities required of all our employees,
including our executive officers. Generally, we believe that
executive base salaries should be near (e.g., within 10%) the
median of the range of salaries for executives in similar
positions at comparable companies determined in a manner
consistent with the PM&P report, but with variations as
dictated by individual circumstances. Base salaries are
generally reviewed annually by our Compensation Committee in
February and changes are effective in late March/early April of
that year. In making base salary decisions, the Committee takes
into account a variety of factors, including the level of the
individuals responsibility, the length of time the
individual has been in that position, the ability to replace the
individual and the current base salary of the individual. In
late February 2009, the Compensation Committee increased the
salaries of our executive officers for 2009 (effective March
2009) in accordance with our standard annual compensation
review with reference to the PM&P study conducted in late
2007. The 2009 base salaries for the named executive officers
were set consistent with our philosophy of keeping salaries near
the median derived from the PM&P study. Increases were in
the range of 2.8% to 3.0%, with the exception of
Mr. Pesicka, who received an 8.8% increase, in light of his
strong performance, a review of the market data developed by
PM&P as described above, and an internal comparison to the
salaries for Messrs. Herrema and Malus.
Base salaries were increased as reflected in the table below.
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
|
Prior Base Salary
|
|
|
|
Base Salary as of March 2009
|
|
Marc N. Casper
|
|
|
$
|
717,500
|
|
|
|
$
|
739,000
|
|
Peter M. Wilver
|
|
|
$
|
582,500
|
|
|
|
$
|
600,000
|
|
Gregory J. Herrema
|
|
|
$
|
447,500
|
|
|
|
$
|
460,030
|
|
Alan J. Malus
|
|
|
$
|
532,500
|
|
|
|
$
|
547,410
|
|
Edward A. Pesicka
|
|
|
$
|
423,000
|
|
|
|
$
|
460,030
|
|
Marijn E. Dekkers
|
|
|
$
|
1,182,500
|
|
|
|
$
|
1,218,000
|
|
|
|
|
|
|
|
|
|
|
|
|
In connection with his appointment as President and Chief
Executive Officer of the Company, Mr. Casper received a
base salary increase effective September 15, 2009, to
$930,000. (See Chief Executive Officer Promotion
below.)
Annual
Cash Incentive Bonus
Annual cash incentive awards for the Companys executive
officers for 2009 were granted under the Companys 2008
Annual Incentive Award Plan (the 162(m) Plan), which
was approved by the stockholders of the Company at its 2008
Annual Meeting of Stockholders. The 162(m) Plan was adopted to
preserve the tax deductibility of the annual bonus that may be
earned by executive officers of the Company. The actual amounts
paid are subject to the application by the Compensation
Committee of negative discretion under the 162(m) Plan, as
described below.
Under the 162(m) Plan, in the first quarter of a calendar year
the Compensation Committee selects a performance goal for the
year. For 2009, the Committee selected the financial measure of
earnings before interest, taxes and amortization, excluding the
impact of restructurings, discontinued operations, extraordinary
items, cost of revenues charges associated with acquisitions or
restructurings, gains/losses from the sale of a business or real
estate, the early retirement of debt and debt facilities and
other unusual or nonrecurring items, the cumulative effects of
accounting changes, tax provisions/benefits related to the
previous items, benefits from tax credit carryforwards, the
impact of significant tax audits or events, and certain other
items (Adjusted Operating Income). The Committee
selected this financial measure, as opposed to an income measure
computed
Page 15
under generally accepted accounting principles (GAAP), because
this measure is consistent with how management measures and
forecasts the Companys performance, especially when
comparing such results to previous periods or forecasts. The
maximum award payable in any year under the 162(m) Plan to an
executive officer is $5,000,000. Each executive officer was
awarded a percentage of Adjusted Operating Income for the year,
subject to the right of the Committee to lower, but not raise,
the actual bonuses paid. In February 2010, the Compensation
Committee elected to lower the 2009 bonuses payable under the
162(m) Plan to the amounts computed in accordance with the
process described below for the Companys annual incentive
program for the year based on the Compensation Committees
determinations as to the level of achievement of the
supplemental performance measures under the Companys
annual incentive program for 2009.
Typically, in the first quarter of a calendar year, the
Compensation Committee also establishes a target incentive cash
award amount under the Companys annual incentive program
for each officer of the Company, including executive officers.
This amount, which is a percentage of base salary, is determined
by the Compensation Committee based on the salary level of the
officer, the position of the officer within the Company and
input from the compensation consultant. The amount actually
awarded to an officer, which can range from 0 to 200% of target,
varies primarily based on performance of the Company as a whole
with respect to financial and non-financial measures, but is
subject to adjustment based on the Committees subjective
evaluation of an officers contributions to those results.
The Committee generally sets the goals such that the target
payout (100% of target bonus) represents attractive financial
performance within our industry and can be reasonably expected
to be achieved; and payouts above 150% of this target require
outstanding performance.
Because of the uncertainty regarding the duration and extent of
the recent global recession, the Compensation Committee elected
to split 2009 into two six-month periods for purposes of
selecting annual incentive compensation financial criteria, in
order to provide an opportunity to reassess mid-year the
appropriateness of the goals for the second six months of 2009.
For the first six months of 2009, the financial measures
established by the Compensation Committee under the
Companys annual incentive program were (i) revenue
(adjusted for the impact of acquisitions and divestitures and
for foreign currency changes) and (ii) earnings (adjusted
for restructuring charges and certain other items of income or
expense) before interest, taxes and amortization as a percentage
of revenue. For both of the financial measures, the
Companys actual performance was measured relative to the
Companys internal operating goals for the first six months
of 2009. In July, the Committee established different revenue
and earnings as a percentage of revenue performance metrics for
the second half of 2009 for assessing the performance of the
executives under the Companys annual cash incentive
program for that period. The weighting of the financial measures
for the first six months of 2009 was as follows: 35% for the
revenue growth goal and 35% for the earnings as a percentage of
revenue goal. The remaining 30% was based on company-wide,
non-financial measures, which would be measured at the end of
the year for all of 2009, and were as follows: the achievement
of employee and customer allegiance goals, increased new product
introduction, organic revenue growth relative to the
Companys peer group, the completion of certain information
technology investments, and the continuation of building a
diverse workforce. For the revenue growth element for the first
half of 2009, the baseline target (for 100% payout) was -5.77%
growth and actual results were -6.23%, yielding a payout of 88%
of target. For the earnings as a percentage of revenue element,
the baseline target was 16.23% of revenue at an assumed revenue
decline of 5.77%. The actual results were 16.20% at the actual
revenue decline of 6.23%, which translated to a payout of 106%
of target, reflecting the difficulty in maintaining the earnings
margin in light of decreasing revenue. The weighting of the
financial measures for the second six months of 2009 was also
35% for the revenue growth goal and 35% for the adjusted
earnings as a percentage of revenue goal. For the revenue growth
element for the second half of 2009, the baseline target (for
100% payout) was -1.78% growth and actual results were -0.27%,
yielding a payout of 138% of target. For the earnings as a
percentage of revenue element, the baseline target was 17.20% of
revenue at an assumed revenue decline of 1.78% and the actual
results were 17.64% at the actual revenue decline of 0.27%,
which translated to a payout of 140% of target. For the revenue
growth element, combined first and second half results yielded a
payout of 113% of target for the full year. For the earnings as
a percentage of revenue element, combined first and second half
results yielded a payout of 123% of target. The Committee
concluded that actual achievement against the non-financial
measures was at a 100% payout level.
Page 16
The process described above resulted in a preliminary overall
achievement calculation of 113% of target bonus for each of the
named executive officers. In light of unprecedented economic
conditions that existed in 2009, Mr. Casper recommended and
the Committee agreed that Messrs. Casper and Wilver (as
corporate executives) would receive bonuses at 100% of target,
rather than at 113% of target. Messrs. Herrema, Malus and
Pesicka (as operating executives) were awarded 90%, 120% and
120% of target bonus, respectively, to reflect the performances
of the operating businesses which they manage.
The target bonus awards and actual bonus awards for 2009 for the
named executive officers were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Target Bonus as a
|
|
|
|
|
|
|
|
|
|
Name
|
|
|
Percentage of Salary
|
|
|
|
Target Bonus Award
|
|
|
|
Actual Bonus Award
|
|
Marc N. Casper(1)
|
|
|
|
115
|
%
|
|
|
$
|
824,533
|
|
|
|
$
|
824,533
|
|
Peter M. Wilver
|
|
|
|
75
|
%
|
|
|
$
|
450,000
|
|
|
|
$
|
450,000
|
|
Gregory J. Herrema
|
|
|
|
70
|
%
|
|
|
$
|
322,021
|
|
|
|
$
|
289,819
|
|
Alan J. Malus
|
|
|
|
70
|
%
|
|
|
$
|
383,187
|
|
|
|
$
|
459,824
|
|
Edward A. Pesicka
|
|
|
|
70
|
%
|
|
|
$
|
322,021
|
|
|
|
$
|
386,425
|
|
Marijn E. Dekkers
|
|
|
|
125
|
%
|
|
|
$
|
1,522,500
|
|
|
|
$
|
0(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
In connection with his appointment as President and Chief
Executive Officer of the Company, Mr. Caspers bonus
target was increased, effective September 15, 2009, to
115%. Prior to that his 2009 bonus target was 95%. The target
and actual award for the year was pro-rated, using the salaries
and target bonus percentages for Mr. Caspers two
positions held during the year. |
|
(2) |
|
Mr. Dekkers was not eligible to participate in either half
of the 2009 program due to his resignation as President and
Chief Executive Officer effective October 15, 2009. |
Stock
Option and Restricted Stock Awards
Our equity award program is the primary vehicle for offering
long-term incentives to our executives. We believe that equity
grants provide our executives with a strong link to our
long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In
addition, the vesting feature of our equity grants should
further our goal of executive retention because this feature
provides an incentive to our executives to remain in our employ
during the vesting period. In determining the size of equity
grants to our executives, our Compensation Committee considers
the recommendations of the chief executive officer with respect
to awards to our executives other than the chief executive
officer, and input from the independent directors of the Board
with respect to awards to our chief executive officer. The
Committee then decides how much of these values should be
delivered by each of the long-term incentive vehicles utilized
by the Company, such as stock options, restricted stock units or
restricted stock awards.
We typically make an initial equity award of stock options to
new executives when they become executives and to newly promoted
executives to reflect their new responsibilities, and annual
equity grants in late February as part of our overall
compensation program. Our equity awards have typically taken the
form of stock options and restricted stock grants, both
performance-based and time-based. In February 2009 the Committee
decided to grant restricted stock units rather than shares of
restricted stock, as described below. Because restricted shares
and restricted stock units have a built-in value at the time the
grants are made, we generally grant significantly fewer shares
of restricted stock than the number of stock options we would
grant for a similar purpose. All grants of options, restricted
stock and restricted stock units to our officers are approved by
the Compensation Committee. The timing of the Compensation
Committee meeting in late February is such that the meeting
occurs after we have publicly released earnings for the
just-completed year. We generally intend that the annualized
value of equity awards to our named executive officers at the
time of grant will approximate the median market consensus of
companies in our compensation peer groups as determined in a
manner consistent with the PM&P report.
Page 17
Typically, the stock options we grant to our named executive
officers vest over the first three to five years of a seven-year
option term, and time-based restricted stock awards vest equally
over three years. Vesting normally ceases upon termination of
employment, except for acceleration upon certain qualifying
retirements, death, disability, and in the case of certain
terminations for Mr. Casper (see Agreements with
Named Executive Officers; Potential Payments upon Termination or
Change in Control on page 33). Stock option exercise
rights normally cease for officers other than Mr. Casper
shortly after termination, except for in the cases of death,
disability and qualifying retirement. Prior to the exercise of
an option, the holder has no rights as a stockholder with
respect to the shares subject to such option, including voting
rights and the right to receive dividends or dividend
equivalents. Prior to the vesting of restricted stock, the
holder has no right to transfer the shares but has voting rights
and the right to receive dividends (if being paid) with respect
to the shares. In February 2009 we began granting restricted
stock units to our named executive officers instead of
restricted stock. The decision to grant restricted stock units
was intended to minimize potential unintended tax consequences
for those employees approaching retirement eligibility. Prior to
the vesting of restricted stock units (which represent a right
in the future to receive shares), the holder has no right to
transfer, vote, or receive dividends with respect to the
underlying shares.
Our practice is to set the exercise price of stock options to
officers to equal the closing price of our Common Stock on the
New York Stock Exchange on the date the grant is approved by the
Compensation Committee or the Employee Equity Committee. Newly
hired or promoted employees, other than officers, normally are
granted stock options by the Employee Equity Committee, which
consists of Mr. Casper. These grants are made once per
quarter, after we have publicly released earnings for the
previous quarter. Grants over 25,000 shares to any
individual, and all grants to officers, may only be approved by
the Compensation Committee.
On February 26, 2009, in connection with the normal
compensation cycle, the Committee granted stock options, and
time-based and performance-based restricted stock units to
Messrs. Wilver, Herrema, Malus and Pesicka. PM&P
provided the Committee with a market consensus median grant
level (in dollars) for each of Messrs. Wilver, Herrema,
Malus and Pesicka. The Committee adjusted these amounts to
reflect its judgment on matters of internal fairness, the impact
of broader economic conditions on the Companys stock
price, and the retentive and incentive value of prior grants to
these individuals. The adjusted amounts were then converted to
numbers of stock options and restricted stock units, with 40% of
the value being delivered through stock options, 30% through
time-based restricted stock units, and 30% through
performance-based restricted stock units. The Committee adopted
this allocation because it supports our strategy of providing
executives with a balanced portfolio of equity vehicles and is
reflective of market practice for our peer companies. With
respect to the performance-based restricted stock units, the
executives would have the ability to earn up to 160% of the
target number of shares based on the Companys achievement
of the maximum performance metric.
The 2009 stock options and time-based restricted stock units
vest in equal annual installments over the three-year period
commencing on the date of grant (i.e., the first
1/3
of a stock option or restricted stock unit would vest on the
first anniversary of the date of grant) so long as the executive
officer is employed by the Company on each such date (subject to
certain exceptions).
In connection with the awards of performance-based restricted
stock units, the Compensation Committee adopted as a performance
goal a range of improvement in modified earnings per share
(which we define as adjusted earnings per share excluding the
impact of share buybacks effected in 2009). If the
Companys 2009 modified EPS were equal to or greater than
$2.59, then the executives would be entitled to a number of
shares ranging from 60% to 160% of the target number of shares
granted. Modified EPS of $3.01 for 2009 led to an actual payout
of 94.29% of the target number of units for each executive.
One-third of the total number of units earned vested in February
2010, and the same number of restricted shares will vest on both
the first anniversary and the second anniversary of this vesting
date so long as the executive officer is employed by the Company
on each such date (subject to certain exceptions).
Page 18
Chief
Executive Officer Promotion
On October 15, 2009, Marc N. Casper, then Executive Vice
President and Chief Operating Officer of the Company, became
President and Chief Executive Officer of the Company. In
connection with this promotion, the Committee engaged PM&P
to assist it in selecting an appropriate compensation level for
Mr. Casper. PM&Ps report and recommendations
were based on research involving eight large company internal
CEO promotions over the 18 months prior to
Mr. Caspers promotion. These eight companies were:
Advanced Micro Devices, Inc., Alcoa, Inc., Anixter Inc., Arrow
Electronics, Inc., Dover Corporation, Eastman Chemical Company,
W. W. Grainger, Inc. and Xerox Corporation. The $2 million
target cash compensation approved for Mr. Casper by the
Committee (a base salary of $930,000 and a bonus target of 115%
of base salary) was in line with the data presented in the
PM&P study and amounted to a 38% increase in total target
cash compensation. These compensation changes were retroactive
to September 15, 2009, the day the Board voted to promote
him to Chief Executive Officer.
PM&P also provided market research to the Committee
relating to equity grants for Mr. Casper in connection with
his promotion. The PM&P report concluded that there were
wide variations in promotional equity grants for the eight large
companies studied. PM&P also recommended updates to the
Companys peer groups (from the December
2007 PM&P report) in connection with this report, in
order to take into consideration recent business combinations
and other factors, such as changes in peer company profiles
(including size and business model) since the earlier report.
Based on these recommendations, the Committee used the following
peer group rosters.
The updated core peer group represents companies most similar to
Thermo Fisher in terms of size and industry. The companies
included in the core peer group are:
|
|
|
Agilent Technologies Inc.
|
|
Baxter International Inc.
|
Becton, Dickinson and Company
|
|
Boston Scientific Corporation
|
Danaher Corporation
|
|
Quest Diagnostics Incorporated
|
Stryker Corporation
|
|
Medtronic, Inc.
|
The updated small competitors peer group represents companies
that are similar to Thermo Fisher in product or service
offerings, but have significantly lower revenues than Thermo
Fisher. The small competitors peer group consists of:
|
|
|
Beckman Coulter, Inc.
|
|
PerkinElmer, Inc.
|
Millipore Corporation
|
|
Waters Corporation
|
Roper Industries, Inc.
|
|
Life Technologies Corporation
|
Varian, Inc.
|
|
Sigma-Aldrich Corporation
|
C.R. Bard, Inc.
|
|
Bio Rad Laboratories, Inc.
Zimmer Holdings, Inc.
|
PM&P also provided research relating to the size of annual
equity grants to CEOs for the companies in the Companys
core peer group and small competitors peer group (adjusting to
$10 billion in sales), and isolated grants to new CEOs with
less than four years of tenure (at Agilent, Becton Dickinson,
Medtronic, PerkinElmer, Sigma-Aldrich and Zimmer Holdings).
After adjusting to $10 billion in sales, the annual grant
value for this subset of companies approximated $6 million.
The Committee added 30% to this median annual grant award value
to balance the extended vesting schedules, the one year delay in
delivery of the restricted stock units after vesting, the
required holding periods for shares issued upon vesting of
restricted stock units, the greater risk from having a
significant portion of the grant value in performance-based
vehicles, and the removal of the Section 280G excise tax
gross-up
that was included in Mr. Caspers previous change in
control agreement. The equity grants approved by the Committee
for Mr. Casper represent the equivalent of 3.5 years
of annual grants at this level, in order to maximize the
retention value of the grants. The terms of these grants are
described in greater detail below.
In November 2009, Mr. Casper was granted options to
purchase 600,000 shares of the Companys Common Stock.
These options (a) vest in equal annual installments over
the five-year period commencing on the second anniversary of the
date of grant (i.e., the first
1/5
of the stock option grant would vest on the second anniversary
of the date of grant) so long as Mr. Casper is employed by
the Company on each such date
Page 19
(subject to certain exceptions), (b) have an exercise price
equal to $46.56, and (c) have a term of 10 years from
the grant date.
Mr. Casper was also granted performance-based options to
purchase 100,000 shares of the Companys Common Stock.
The options vest in one installment on the day the performance
goal related to the Companys stock price for any 20
consecutive trading days ending during the period
October 15, 2009 through November 21, 2019 has been
achieved, and the performance goal related to the Companys
total shareholder return between October 15, 2009 and the
date the performance goal related to the Companys stock
price, or later (but no later than November 21, 2019), is
achieved, relative to the performance of the S&P 500
Industrials Index for the same period, so long as
Mr. Casper is employed by the Company on each such date
(subject to certain exceptions). The options have an exercise
price equal to $46.56, and a term of 10 years from the
grant date. Because the level of achievement required to vest is
a function of external market factors, the likelihood of any
particular outcome is not ascertainable; however, for financial
reporting purposes the grant date fair value of the award has
been estimated based on a Monte Carlo simulation of a variety of
outcomes. See footnotes to the Summary Compensation Table on
page 22.
Mr. Casper was granted 200,000 time-based restricted stock
units of the Company. The time-based restricted stock units vest
in equal annual installments over the four-year period
commencing on February 15, 2012 (i.e., the first 1/4 of the
restricted stock unit grant would vest on February 15,
2012) so long as Mr. Casper is employed by the Company
on each such date (subject to certain exceptions).
Mr. Casper was granted up to 400,000 performance-based
restricted stock units of the Company. The number of
performance-based restricted stock units to be earned (from 0 to
400,000) is based on the Companys total shareholder return
for each of the applicable measurement periods, relative to the
performance of the S&P 500 Industrials Index for the same
period, assuming continued employment (subject to certain
exceptions). From 0 to 100,000 performance-based restricted
stock units will vest after each of the following four
measurement periods: (1) October 15, 2009 through
February 15, 2012, (2) October 15, 2009 through
February 15, 2013, (3) October 15, 2009 through
February 15, 2014, and (4) October 15, 2009
through February 15, 2015. Because the level of achievement
required to vest is a function of external market factors, the
likelihood of any particular outcome is not ascertainable;
however, for financial reporting purposes the grant date fair
value of the award has been estimated based on a Monte Carlo
simulation of a variety of outcomes. See footnotes to the
Summary Compensation Table on page 22.
Shares issuable upon vesting of the 2009 restricted stock units
would be delivered to Mr. Casper on the first anniversary
of the applicable vesting date, subject to certain exceptions.
Mr. Casper is required to hold 50% of the shares delivered
(net of shares withheld for taxes) for a period of two years
after delivery, subject to certain exceptions.
Stock
Ownership Policy
The Compensation Committee has established a stock holding
policy that the chief executive officer holds shares of Common
Stock equal in value to at least four times his annual base
salary and that each other executive officer hold shares of
Common Stock equal in value to at least two times his or her
annual base salary. For purposes of this policy, shares of
time-based restricted Common Stock are counted towards the
target. All of our named executive officers are currently in
compliance with this policy.
Benefits
and Other Compensation
We maintain broad-based benefits that are provided to all
employees, including health and dental insurance, life and
disability insurance and a 401(k) plan. Executives are eligible
to participate in all of our employee benefit plans, in each
case on the same basis as other employees. The 401(k) plan is a
tax-qualified retirement savings plan pursuant to which all
U.S. based employees, including officers, are able to
contribute a percentage of their annual salary up to the limit
prescribed by the Internal Revenue Service (the IRS)
to the 401(k) plan on a before-tax basis. The Company matches
contributions made by employees to the 401(k) plan, dollar for
dollar, up to the first 6 percent of compensation deferred
by the employee to the plan. Employees
Page 20
were capped at contributing 6% of $245,000 for 2009 in
accordance with the IRS annual compensation limit. All
contributions to the 401(k) plan as well as any matching
contributions are fully-vested upon contribution.
The named executive officers, in addition to certain other
U.S.-based
eligible executives, are entitled to participate in the
Companys Deferred Compensation Plan. Pursuant to the
Deferred Compensation Plan, an eligible employee can defer
receipt of his or her annual base salary
and/or bonus
until he or she ceases to serve as an employee of the Company or
until a future date while the participant continues to be an
employee of the Company. The Deferred Compensation Plan is
discussed in further detail under the heading Nonqualified
Deferred Compensation For 2009 on page 30. Amounts
deferred under this plan can be invested in an array of mutual
funds and vehicles administered by The Newport Group. The
Company does not guarantee any above-market interest rates or
rates of return on these deferred amounts. On January 1,
2009, the Company began matching 100% of the first 6% of pay
that is deferred into the Deferred Compensation Plan over the
IRS annual compensation limit for 401(k) purposes. In connection
with the introduction of this new match benefit, the Committee
approved a one-time credit in the deferred compensation accounts
of eligible Plan participants who had not previously elected to
defer 6% of their 2008 bonus, payable in March 2009. (Internal
Revenue Code Section 409A effectively prohibited these
eligible participants from making deferrals of the 2008 bonus in
2008 after the new match feature was approved.) In order to
receive this one-time credit, eligible plan participants who did
not elect to defer a portion of their 2008 bonus and who are
officers of the Company were also required to defer at least 6%
of their 2009 salary to the plan.
The Company provides officers with perquisites and other
personal benefits that the Company and the Compensation
Committee believe are reasonable and consistent with its overall
compensation program to better enable the Company to attract and
retain superior employees for key positions. Each named
executive officer receives supplemental long-term disability and
life insurance, and access to emergency medical service through
Massachusetts General Hospitals global hospital network.
Additionally, the Company provides a $3 million term life
insurance policy to Marc Casper. Attributed costs of the
personal benefits described above for the named executive
officers for 2009 are described in the Summary
Compensation Table on page 22.
Severance
and Change in Control Benefits
Pursuant to our equity plans and agreements we have entered into
with our executives, in the event of the termination of their
employment under certain circumstances or a change in control,
they are entitled to specified benefits. We have provided more
detailed information about these benefits, along with estimates
of their value under various circumstances, under the caption
Agreements with Named Executive Officers; Potential
Payments Upon Termination or Change in Control on
page 33. We believe providing these benefits helps us
compete for executive talent and that our severance and change
in control benefits are generally in line with severance
packages offered to comparable executives at other companies.
We have executive change in control retention agreements with
our executives that provide cash and other severance benefits if
there is a change in control of the Company and their employment
is terminated by the Company without cause or by the
individual for good reason, as those terms are
defined therein, in each case within 18 months thereafter.
We also have an executive severance policy that provides
severance benefits to our executives (other than
Mr. Casper) in the event their employment is terminated by
the Company without cause (as such term is defined
therein) in the absence of a change in control.
Mr. Caspers severance arrangements are provided in a
separate agreement between him and the Company. The change in
control retention agreements and executive severance
arrangements are described in greater detail under the caption
Agreements with Named Executive Officers; Potential
Payments Upon Termination or Change in Control on
page 33.
In February 2009, the Committee approved a new form of executive
change in control agreements for executives joining the Company
after February 2009. The new form of change in control agreement
eliminates any tax
gross-up
provision, as the Company does not intend to extend tax
gross-ups in
future compensation arrangements.
Page 21
Tax and
Accounting Considerations
Deductibility
of Executive Compensation
The Compensation Committee considers the potential effect of
Section 162(m) of the Internal Revenue Code of 1986 as
amended (the Code), in designing its compensation
program, but reserves the right to use its independent judgment
to approve nondeductible compensation, while taking into account
the financial effects such action may have on the Company.
Section 162(m) limits the tax deduction available to public
companies for annual compensation that is paid to the
Companys chief executive officer and three other most
highly paid executive officers (other than the chief financial
officer) in excess of $1,000,000, unless the compensation
qualifies as performance-based or is otherwise
exempt from Section 162(m). Stock options,
performance-based restricted stock and restricted stock unit
awards and annual incentive cash bonuses for the executive
officers are intended to qualify for the deduction. However, the
portion of the compensation for Messrs. Casper and Malus
that was in excess of $1,000,000 individually and that does not
qualify as performance-based compensation was approximately
$485,000 and $266,452 for Messrs. Casper and Malus,
respectively, which will not be deductible for 2009.
Accounting
Considerations
Accounting considerations also play an important role in the
design of our executive compensation programs and policies. ASC
718 requires us to expense the cost of stock-based compensation
awards. We consider the relative impact in terms of accounting
cost in addition to other factors such as stockholder dilution,
retentive impact, and motivational impact when selecting
long-term equity incentive instruments.
Compensation
Committee Report
The Compensation Committee of the Company has reviewed and
discussed the Compensation Discussion and Analysis required by
Item 402(b) of
Regulation S-K
with management and, based on such review and discussions, the
Compensation Committee recommended to the Board that the
Compensation Discussion and Analysis be included in this proxy
statement.
THE COMPENSATION COMMITTEE
Tyler Jacks
Stephen P. Kaufman
Thomas J. Lynch
Scott M. Sperling
Elaine S. Ullian
Page 22
Summary
Compensation Table
The following table summarizes compensation for services to the
Company earned during the last three fiscal years by the
Companys chief executive officer, chief financial officer,
the three other most highly compensated executive officers of
the Company during 2009, and the former chief executive officer.
The executive officers listed below are collectively referred to
in this proxy statement as the named executive
officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
|
Option
|
|
|
|
Incentive Plan
|
|
|
|
Compensation
|
|
|
|
All Other
|
|
|
|
|
|
Name and
|
|
|
|
|
|
|
Salary
|
|
|
|
Awards
|
|
|
|
Awards
|
|
|
|
Compensation
|
|
|
|
Earnings
|
|
|
|
Compensation
|
|
|
|
Total
|
|
Principal Position
|
|
|
Year
|
|
|
|
($)
|
|
|
|
($)(1)
|
|
|
|
($)(2)
|
|
|
|
($)(3)
|
|
|
|
($)(4)
|
|
|
|
($)(5)
|
|
|
|
($)
|
|
Marc N. Casper
President and Chief Executive Officer
|
|
|
|
2009
|
|
|
|
|
$790,220
|
|
|
|
|
$19,591,774
|
|
|
|
|
$12,809,444
|
|
|
|
|
$824,533
|
|
|
|
|
$159,966
|
|
|
|
|
$107,837
|
|
|
|
|
$34,283,774
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
$701,250
|
|
|
|
|
$1,430,762
|
|
|
|
|
$6,228,750
|
|
|
|
|
$823,266
|
|
|
|
|
|
|
|
|
|
$86,253
|
|
|
|
|
$9,270,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
|
|
$657,498
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$825,775
|
|
|
|
|
$30,080
|
|
|
|
|
$44,173
|
|
|
|
|
$1,557,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter M. Wilver
Senior Vice President
and Chief Financial Officer
|
|
|
|
2009
|
|
|
|
|
$595,758
|
|
|
|
|
$1,126,320
|
|
|
|
|
$740,940
|
|
|
|
|
$450,000
|
|
|
|
|
$15,848
|
|
|
|
|
$67,429
|
|
|
|
|
$2,996,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
$566,250
|
|
|
|
|
$1,185,857
|
|
|
|
|
|
|
|
|
|
$547,886
|
|
|
|
|
|
|
|
|
|
$58,621
|
|
|
|
|
$2,358,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
|
|
$535,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$513,065
|
|
|
|
|
|
|
|
|
|
$32,623
|
|
|
|
|
$1,080,688
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory J. Herrema(6)
Senior Vice President
|
|
|
|
2009
|
|
|
|
|
$456,992
|
|
|
|
|
$1,299,600
|
|
|
|
|
$855,420
|
|
|
|
|
$289,819
|
|
|
|
|
$108,892
|
|
|
|
|
$37,942
|
|
|
|
|
$3,057,665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alan J. Malus
Senior Vice President
|
|
|
|
2009
|
|
|
|
|
$544,078
|
|
|
|
|
$1,299,600
|
|
|
|
|
$855,420
|
|
|
|
|
$459,824
|
|
|
|
|
$60,213
|
|
|
|
|
$65,480
|
|
|
|
|
$3,284,615
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
$520,000
|
|
|
|
|
$1,121,408
|
|
|
|
|
$835,500
|
|
|
|
|
$477,940
|
|
|
|
|
$2,808
|
|
|
|
|
$55,198
|
|
|
|
|
$3,012,854
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
|
|
$495,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$507,500
|
|
|
|
|
$2,698
|
|
|
|
|
$26,688
|
|
|
|
|
$1,031,886
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Pesicka(7)
Senior Vice President
|
|
|
|
2009
|
|
|
|
|
$451,754
|
|
|
|
|
$1,299,600
|
|
|
|
|
$855,420
|
|
|
|
|
$386,425
|
|
|
|
|
$34,850
|
|
|
|
|
$54,075
|
|
|
|
|
$3,082,124
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marijn E. Dekkers(8)
Former President and Chief Executive Officer
|
|
|
|
2009
|
|
|
|
|
$955,644
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$691,870
|
|
|
|
|
$61,215
|
|
|
|
|
$1,708,729
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
$1,163,750
|
|
|
|
|
$284,600
|
|
|
|
|
$15,250,460
|
|
|
|
|
$1,865,643
|
|
|
|
|
|
|
|
|
|
$141,119
|
|
|
|
|
$18,705,572
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
|
|
$1,125,000
|
|
|
|
|
$225,050
|
|
|
|
|
|
|
|
|
|
$1,926,563
|
|
|
|
|
$181,725
|
|
|
|
|
$36,496
|
|
|
|
|
$3,494,834
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) These amounts represent the
aggregate grant date fair value of restricted stock and
restricted stock unit awards made during 2009, 2008 and 2007,
respectively, calculated in accordance with the Companys
financial reporting practices. For information on the valuation
assumptions with respect to these awards, refer to note 5
of the Thermo Fisher financial statements in the
Form 10-K
for the year ended December 31, 2009, as filed with the
SEC. For the November 21, 2009 performance-based restricted
stock unit granted to Mr. Casper, this amount reflects the
grant date fair value of such award using a Monte Carlo
simulation model. The value of this award at the grant date
assuming that the highest level of performance conditions was
achieved is $18,624,000. For performance-based restricted stock
unit awards made in February 2009 to Messrs. Wilver,
Herrema, Malus and Pesicka, these amounts reflect the grant date
fair value of such awards based upon the probable outcome at the
time of grant. The value of these awards at the grant date
assuming that the highest level of performance conditions was
achieved was $901,056, $1,039,680, $1,039,680 and $1,039,680 for
Messrs. Wilver, Herrema, Malus and Pesicka, respectively.
For performance-based restricted stock unit awards made in
February 2008 to Messrs. Casper, Wilver and Malus, these
amounts reflect the grant date fair value of such awards based
upon the probable outcome at the time of grant. The value of
these awards at the grant date assuming that the highest level
of performance conditions was achieved was $974,136, $807,392,
and $763,512 for Messrs. Casper, Wilver and Malus,
respectively. The amounts reflected in this column do not
represent the actual amounts paid to or realized by the named
executive officer for these awards during fiscal years 2009,
2008 or 2007.
(2) These amounts represent the
aggregate grant date fair value of stock option awards made
during 2009, 2008 and 2007, respectively, calculated in
accordance with the Companys financial reporting
practices. For
Page 23
information on the valuation assumptions with respect to these
awards, refer to note 5 of the Thermo Fisher financial
statements in the
Form 10-K
for the year ended December 31, 2009, as filed with the
SEC. For the November 21, 2009 performance-based stock
option granted to Mr. Casper, this amount reflects the
grant date fair value of such award using a Monte Carlo
simulation model. The value of this award at the grant date
assuming that the highest level of performance conditions was
achieved is $2,215,605. These amounts do not represent the
actual amounts paid to or realized by the named executive
officer for these awards during fiscal years 2009, 2008 or 2007.
No stock options were granted to the named executive officers in
2007.
(3) Reflects compensation earned
for the year but paid early in the subsequent year.
(4) For Messrs. Casper,
Wilver, Herrema, Pesicka, and Dekkers (and Mr. Malus in
2008 and 2009), the amounts presented in this column include the
entire amount of earnings (if any) for the year under investment
alternatives on deferred compensation balances. For
Messrs. Malus and Pesicka, the amounts presented in this
column also include the actuarial increase in the present value
of their benefits under the Thermo Fisher Retirement Plan during
the year ($2,808 for Mr. Malus in 2008, and $2,808 and
$2,104 for Messrs. Malus and Pesicka, respectively, for
2009).
(5) Under SEC rules and
regulations, if the total value of all perquisites and personal
benefits is $10,000 or more for any named executive officer,
then each perquisite or personal benefit, regardless of its
amount, must be identified by type. If perquisites and personal
benefits are required to be reported for a named executive
officer, then each perquisite or personal benefit that exceeds
the greater of $25,000 or 10% of the total amount of perquisites
and personal benefits for that officer must be quantified and
disclosed in a footnote. The amounts presented in this column
include (a) matching contributions made on behalf of the
named executive officers by the Company pursuant to the
Companys 401(k) Plan, (b) premiums paid by the
Company with respect to long-term disability insurance for the
benefit of the named executive officers, (c) with respect
to Messrs. Casper and Dekkers, premiums paid by the Company
for a term life insurance policy for the benefit of
Messrs. Casper and Dekkers, respectively, (d) premiums
paid by the Company with respect to supplemental group term life
insurance, (e) access to emergency medical service through
Massachusetts General Hospitals global hospital network,
and (f) matching contributions made on behalf of the named
executive officers by the Company pursuant to the Companys
Non-Qualified Deferred Compensation Plan. For 2009, the dollar
value of the principal components of these benefits was
(1) $14,700 each for Messrs. Casper, Wilver, Herrema,
Malus, Pesicka and Dekkers for matching 401(k) contributions,
(2) $2,244, $3,010, $2,444, $3,784, $2,720 and $2,657 for
Messrs. Casper, Wilver, Herrema, Malus, Pesicka and
Dekkers, respectively, for long-term disability insurance
premiums, (3) $11,875 and $3,260 for a term life insurance
policy for Messrs. Casper and Dekkers, respectively, and
(4) $77,770, $48,710, $29,157, $46,173, $36,020 and $39,537
for Messrs. Casper, Wilver, Herrema, Malus, Pesicka and
Dekkers, respectively, for matching deferred compensation plan
contributions.
(6) Mr. Herrema became an
executive officer of the Company on May 15, 2008, but was
not a named executive officer for the year ended
December 31, 2008.
(7) Mr. Pesicka became an
executive officer of the Company on July 10, 2008, but was
not a named executive officer for the year ended
December 31, 2008.
(8) Mr. Dekkers resigned from
the Company on September 15, 2009, effective
October 15, 2009.
Page 24
Grants of
Plan-Based Awards For 2009*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
|
|
|
All
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated Future Payouts Under
|
|
|
Estimated Future
|
|
|
Awards:
|
|
|
Awards:
|
|
|
Exercise or
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity Incentive Plan Awards
|
|
|
Payouts Under Equity
|
|
|
Number
|
|
|
Number of
|
|
|
Base Price
|
|
|
Grant Date Fair
|
|
|
|
|
|
|
|
|
|
Incentive Plan Awards
|
|
|
of Shares
|
|
|
Securities
|
|
|
of Option
|
|
|
Value of
|
|
|
|
Grant
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
|
|
|
of Stock or
|
|
|
Underlying
|
|
|
Awards
|
|
|
Stock and Option
|
Name
|
|
|
Date
|
|
|
($)
|
|
|
($)(1)
|
|
|
($)
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Units
|
|
|
Options
|
|
|
($/Sh)
|
|
|
Awards ($)(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marc N. Casper
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$824,533
|
|
|
|
|
$1,649,066
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11/21/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0(3
|
)
|
|
|
|
200,000(3
|
)
|
|
|
|
400,000(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$10,279,774
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11/21/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$9,312,000
|
|
|
|
|
|
|
|
|
|
|
11/21/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000(5)
|
|
|
|
$
|
46.56
|
|
|
|
|
$10,812,000
|
|
|
|
|
|
|
|
|
|
|
11/21/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
100,000(6
|
)
|
|
|
|
100,000(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
46.56
|
|
|
|
|
$1,997,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter M. Wilver
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$450,000
|
|
|
|
|
$900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0(7
|
)
|
|
|
|
15,600(7
|
)
|
|
|
|
24,960(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$563,160
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,600(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$563,160
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69,900(9)
|
|
|
|
$
|
36.10
|
|
|
|
|
$740,940
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory J. Herrema
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$322,021
|
|
|
|
|
$644,042
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0(7
|
)
|
|
|
|
18,000(7
|
)
|
|
|
|
28,800(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(9)
|
|
|
|
$
|
36.10
|
|
|
|
|
$855,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alan J. Malus
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$383,187
|
|
|
|
|
$766,374
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0(7
|
)
|
|
|
|
18,000(7
|
)
|
|
|
|
28,800(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(9)
|
|
|
|
$
|
36.10
|
|
|
|
|
$855,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Pesicka
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$322,021
|
|
|
|
|
$644,042
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0(7
|
)
|
|
|
|
18,000(7
|
)
|
|
|
|
28,800(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$649,800
|
|
|
|
|
|
|
|
|
|
|
2/26/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(9)
|
|
|
|
$
|
36.10
|
|
|
|
|
$855,420
|
|
|
|
|
|
|
Marijn E. Dekkers
|
|
|
|
2/26/2009
|
|
|
|
|
0
|
|
|
|
|
$1,522,500
|
|
|
|
|
$3,045,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* All awards made during 2009 were
granted under the Companys 2008 Stock Incentive Plan.
(1) Target awards are based on a
percentage of the named executive officers salary.
(2) These amounts represent the
aggregate grant date fair value of stock option and restricted
stock unit awards made during 2009, calculated in accordance
with the Companys financial reporting practices. For
information on the valuation assumptions with respect to these
awards, refer to note 5 of the Thermo Fisher financial
statements in the
Form 10-K
for the year ended December 31, 2009, as filed with the
SEC. For performance-based awards for Mr. Casper, these
amounts reflect the grant date fair value of each award using a
Monte Carlo simulation model. For performance-based awards for
Messrs. Wilver, Herrema, Malus and Pesicka, these amounts
reflect the grant date fair value of each award based upon the
probable outcome at the time of grant. Please see the footnotes
to the Summary Compensation Table on page 22 for the grant
date fair value of each award assuming that the highest level of
performance conditions was achieved. The amounts reflected in
this column do not represent the actual amounts paid to or
realized by the named executive officer for these awards during
fiscal year 2009.
(3) Represents the threshold,
target and maximum number of achievable shares pursuant to a
performance-based restricted stock unit award. The number of
performance-based restricted stock units to be earned (from 0 to
400,000) is based on the Companys total shareholder return
for each of the applicable measurement periods, relative to the
performance of the S&P 500 Industrials Index for the same
period, assuming continued employment, subject to certain
exceptions. From 0 to 100,000 performance-based restricted stock
units will vest after each of the following four measurement
periods: (1) October 15, 2009 through
February 15, 2012, (2) October 15, 2009 through
February 15, 2013, (3) October 15, 2009 through
February 15, 2014, and (4) October 15, 2009
through February 15, 2015, assuming continued employment,
subject to certain exceptions.
Page 25
(4) Represents a time-based
restricted stock unit award which vests in equal annual
installments on February 15, 2012, February 15, 2013,
February 15, 2014 and February 15, 2015, so long as
Mr. Casper is employed by the Company on each such date
(subject to certain exceptions).
(5) Options vest in equal annual
installments on November 21, 2011, November 21, 2012,
November 21, 2013, November 21, 2014 and
November 21, 2015, so long as Mr. Casper is employed
by the Company on each such date (subject to certain exceptions).
(6) Represents a performance-based
option grant which vests in one installment on the day the
performance goal related to the Companys stock price for
any 20 consecutive trading days ending during the period
October 15, 2009 through November 21, 2019 has been
achieved, and the performance goal related to the Companys
total shareholder return between October 15, 2009 and the
date the performance goal related to the Companys stock
price, or later (but no later than November 21, 2019), is
achieved, relative to the performance of the S&P 500
Industrials Index for the same period, so long as
Mr. Casper is employed by the Company on each such date
(subject to certain exceptions).
(7) Represents the threshold,
target and maximum number of achievable shares pursuant to a
performance-based restricted stock unit award. In connection
with the awards of performance-based restricted stock units, the
Compensation Committee adopted as a performance goal a range of
improvement in modified earnings per share. If the
Companys 2009 modified EPS were equal to or greater than
$2.59, then the executives would be entitled to a number of
units ranging from 60% to 160% of the target number of units
granted. Modified EPS of $3.01 for 2009 led to an actual payout
of 94.29% of the target number of units for each executive.
One-third of the total number of units earned vested in February
2010, and the same number of restricted units will vest on both
the first anniversary and the second anniversary of this vesting
date so long as the executive officer is employed by the Company
on each such date (subject to certain exceptions).
(8) Represents a time-based
restricted stock unit award which vests in equal annual
installments over a three-year period commencing on the date of
grant (i.e., the first 1/3 of the restricted stock unit grant
would vest on the first anniversary of the date of grant) so
long as the executive officer is employed by the Company on each
such date (subject to certain exceptions).
(9) Options vest in equal annual
installments over the three-year period commencing on the date
of grant (i.e., the first 1/3 of the stock option grant would
vest on the first anniversary of the date of grant) so long as
the executive officer is employed by the Company on each such
date (subject to certain exceptions).
Page 26
Outstanding
Equity Awards at 2009 Fiscal Year-End
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
Market or
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
Payout
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of
|
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unearned
|
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares,
|
|
|
|
Shares,
|
|
|
|
|
Number of
|
|
|
|
Number of
|
|
|
|
of Securities
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
Market Value
|
|
|
|
Units or
|
|
|
|
Units or
|
|
|
|
|
Securities
|
|
|
|
Securities
|
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
|
of Shares or
|
|
|
|
Other
|
|
|
|
Other
|
|
|
|
|
Underlying
|
|
|
|
Underlying
|
|
|
|
Unexercised
|
|
|
|
Option
|
|
|
|
|
|
|
|
Units of
|
|
|
|
Units of Stock
|
|
|
|
Rights
|
|
|
|
Rights
|
|
|
|
|
Unexercised
|
|
|
|
Unexercised
|
|
|
|
Unearned
|
|
|
|
Exercise
|
|
|
|
Option
|
|
|
|
Stock That
|
|
|
|
That Have Not
|
|
|
|
That Have
|
|
|
|
That Have
|
|
|
|
|
Options (#)
|
|
|
|
Options (#)
|
|
|
|
Options
|
|
|
|
Price
|
|
|
|
Expiration
|
|
|
|
Have Not
|
|
|
|
Vested ($)
|
|
|
|
Not
|
|
|
|
Not Vested ($)
|
|
Name
|
|
|
Exercisable
|
|
|
|
Unexercisable (1)
|
|
|
|
(#)
|
|
|
|
($)
|
|
|
|
Date
|
|
|
|
Vested (#)(1)
|
|
|
|
@ $47.69*
|
|
|
|
Vested (#)
|
|
|
|
@$47.69*
|
|
Marc N. Casper
|
|
|
|
190,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$34.86
|
|
|
|
|
2/27/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
151,140
|
|
|
|
|
100,760(2
|
)
|
|
|
|
|
|
|
|
|
$43.37
|
|
|
|
|
11/9/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000
|
|
|
|
|
300,000(3
|
)
|
|
|
|
|
|
|
|
|
$57.58
|
|
|
|
|
5/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000(4
|
)
|
|
|
|
|
|
|
|
|
$46.56
|
|
|
|
|
11/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000(5
|
)
|
|
|
|
$46.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,400(6
|
)
|
|
|
|
$257,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,400(7
|
)
|
|
|
|
$352,906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,138(8
|
)
|
|
|
|
$483,481
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000(9
|
)
|
|
|
|
$9,538,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400,000(10
|
)
|
|
|
|
$19,076,000(11
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter M. Wilver
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$27.40
|
|
|
|
|
2/25/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$34.86
|
|
|
|
|
2/27/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,160
|
|
|
|
|
45,120(2
|
)
|
|
|
|
|
|
|
|
|
$43.37
|
|
|
|
|
11/9/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69,900(12
|
)
|
|
|
|
|
|
|
|
|
$36.10
|
|
|
|
|
2/26/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,419(6
|
)
|
|
|
|
$115,362
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,134(7
|
)
|
|
|
|
$292,530
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,403(8
|
)
|
|
|
|
$400,739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,600(13
|
)
|
|
|
|
$743,964
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,600(14
|
)
|
|
|
|
$743,964(15
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory J. Herrema
|
|
|
|
45,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$27.40
|
|
|
|
|
2/25/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$34.86
|
|
|
|
|
2/27/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$37.93
|
|
|
|
|
5/12/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,360
|
|
|
|
|
26,240(2
|
)
|
|
|
|
|
|
|
|
|
$43.37
|
|
|
|
|
11/9/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,333
|
|
|
|
|
16,667(16
|
)
|
|
|
|
|
|
|
|
|
$57.58
|
|
|
|
|
5/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(12
|
)
|
|
|
|
|
|
|
|
|
$36.10
|
|
|
|
|
2/26/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,200(7
|
)
|
|
|
|
$200,298
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,754(8
|
)
|
|
|
|
$274,408
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(13
|
)
|
|
|
|
$858,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(14
|
)
|
|
|
|
$858,420(15
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alan J. Malus
|
|
|
|
90,840
|
|
|
|
|
60,560(2
|
)
|
|
|
|
|
|
|
|
|
$43.37
|
|
|
|
|
11/9/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
40,000(17
|
)
|
|
|
|
|
|
|
|
|
$58.40
|
|
|
|
|
7/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,340
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$31.305
|
|
|
|
|
12/19/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(12
|
)
|
|
|
|
|
|
|
|
|
$36.10
|
|
|
|
|
2/26/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,250(6
|
)
|
|
|
|
$154,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,800(7
|
)
|
|
|
|
$276,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,946(8
|
)
|
|
|
|
$378,945
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(13
|
)
|
|
|
|
$858,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(14
|
)
|
|
|
|
$858,420(15
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
Market or
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
Payout
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of
|
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unearned
|
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares,
|
|
|
|
Shares,
|
|
|
|
|
Number of
|
|
|
|
Number of
|
|
|
|
of Securities
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
Market Value
|
|
|
|
Units or
|
|
|
|
Units or
|
|
|
|
|
Securities
|
|
|
|
Securities
|
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
|
of Shares or
|
|
|
|
Other
|
|
|
|
Other
|
|
|
|
|
Underlying
|
|
|
|
Underlying
|
|
|
|
Unexercised
|
|
|
|
Option
|
|
|
|
|
|
|
|
Units of
|
|
|
|
Units of Stock
|
|
|
|
Rights
|
|
|
|
Rights
|
|
|
|
|
Unexercised
|
|
|
|
Unexercised
|
|
|
|
Unearned
|
|
|
|
Exercise
|
|
|
|
Option
|
|
|
|
Stock That
|
|
|
|
That Have Not
|
|
|
|
That Have
|
|
|
|
That Have
|
|
|
|
|
Options (#)
|
|
|
|
Options (#)
|
|
|
|
Options
|
|
|
|
Price
|
|
|
|
Expiration
|
|
|
|
Have Not
|
|
|
|
Vested ($)
|
|
|
|
Not
|
|
|
|
Not Vested ($)
|
|
Name
|
|
|
Exercisable
|
|
|
|
Unexercisable (1)
|
|
|
|
(#)
|
|
|
|
($)
|
|
|
|
Date
|
|
|
|
Vested (#)(1)
|
|
|
|
@ $47.69*
|
|
|
|
Vested (#)
|
|
|
|
@$47.69*
|
|
Edward A. Pesicka
|
|
|
|
48,480
|
|
|
|
|
32,320(2
|
)
|
|
|
|
|
|
|
|
|
$43.37
|
|
|
|
|
11/9/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$30.675
|
|
|
|
|
3/7/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,333
|
|
|
|
|
16,667(18
|
)
|
|
|
|
|
|
|
|
|
$58.40
|
|
|
|
|
7/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
64,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$32.30
|
|
|
|
|
7/25/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$31.305
|
|
|
|
|
12/19/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,700(12
|
)
|
|
|
|
|
|
|
|
|
$36.10
|
|
|
|
|
2/26/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,067(7
|
)
|
|
|
|
$193,955
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,572(8
|
)
|
|
|
|
$265,729
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(13
|
)
|
|
|
|
$858,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,000(14
|
)
|
|
|
|
$858,420(15
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Reflects the closing price of the Companys Common
Stock on the New York Stock Exchange on December 31, 2009.
(1) Unexercisable stock options and
unvested shares and units of restricted stock vest as described
in the footnotes below and under certain circumstances described
under the heading Agreements with Named Executive
Officers; Potential Payments Upon Termination or Change in
Control. Unexercisable stock options and unvested shares
and units of restricted stock also vest upon certain other
events such as death, disability, or qualifying retirement.
(2) Represents the balance of a
stock option granted on November 9, 2006, which vests in
equal annual installments on November 9, 2010 and 2011, so
long as the executive officer is employed by the Company on each
such date (subject to certain exceptions).
(3) Represents the balance of a
stock option granted on May 15, 2008, which vests in equal
annual installments on May 15, 2010, 2011, 2012 and 2013,
so long as the executive officer is employed by the Company on
each such date (subject to certain exceptions).
(4) Options vest in equal annual
installments on November 21, 2011, November 21, 2012,
November 21, 2013, November 21, 2014 and
November 21, 2015, so long as Mr. Casper is employed
by the Company on each such date (subject to certain exceptions).
(5) Represents a performance-based
option grant which vests in one installment on the day the
performance goal related to the Companys stock price for
any 20 consecutive trading days ending during the period
October 15, 2009 through November 21, 2019 has been
achieved, and the performance goal related to the Companys
total shareholder return between October 15, 2009 and the
date the performance goal related to the Companys stock
price, or later (but no later than November 21, 2019), is
achieved, relative to the performance of the S&P 500
Industrials Index for the same period, so long as
Mr. Casper is employed by the Company on each such date
(subject to certain exceptions).
(6) Represents the balance of a
performance-based restricted stock award made on
November 9, 2006, which vests on August 17, 2010, so
long as the executive officer is employed by the Company on such
date (subject to certain exceptions).
(7) Represents the balance of a
time-based restricted stock award made on March 5, 2008,
which vests in equal annual installments on March 5, 2010
and 2011, so long as the executive officer is employed by the
Company on each such date (subject to certain exceptions).
Page 28
(8) Represents the balance of a
performance-based restricted stock award made on March 5,
2008, which vests in equal annual installments on
February 26, 2010 and 2011, so long as the executive
officer is employed by the Company on each such date (subject to
certain exceptions).
(9) Represents a time-based
restricted stock unit award which vests in equal annual
installments on February 15, 2012, February 15, 2013,
February 15, 2014 and February 15, 2015, so long as
Mr. Casper is employed by the Company on each such date
(subject to certain exceptions).
(10) Represents the maximum number
of shares that may be earned pursuant to a performance-based
restricted stock unit award made on November 21, 2009. The
number of performance-based restricted stock units to be earned
(from 0 to 400,000) is based on the Companys total
shareholder return for each of the applicable measurement
periods, relative to the performance of the S&P 500
Industrials Index for the same period, assuming continued
employment, subject to certain exceptions. From 0 to 100,000
performance-based restricted stock units will vest after each of
the following four measurement periods:
(1) October 15, 2009 through February 15, 2012,
(2) October 15, 2009 through February 15, 2013,
(3) October 15, 2009 through February 15, 2014,
and (4) October 15, 2009 through February 15,
2015, assuming continued employment, subject to certain
exceptions. In accordance with SEC rules, the maximum number of
shares that may be earned is shown above because in fiscal year
2009 the Company exceeded the target shareholder return
specified in the award relative to the performance of the
S&P 500 Industrials Index for the same period.
(11) Represents the maximum payout
of a performance-based restricted stock unit award made on
November 21, 2009 at $47.69, the Companys closing
stock price on December 31, 2009.
(12) Represents a stock option
granted on February 26, 2009, which vests in equal annual
installments on February 26, 2010, February 26, 2011
and February 26, 2012.
(13) Represents a time-based
restricted stock unit award made on February 26, 2009,
which vests in equal annual installments on February 26,
2010, February 26, 2011 and February 26, 2012.
(14) Represents the target number
of achievable shares pursuant to a performance-based restricted
stock unit award made on February 26, 2009. In connection
with the awards of performance-based restricted stock units, the
Compensation Committee adopted as a performance goal a range of
modified earnings per share for the year ended December 31,
2009. The vesting of the performance-based restricted stock
awards is as follows: up to thirty-three and one-third percent
(331/3%)
of the maximum number of restricted stock units vests on the day
the Compensation Committee certifies the Companys modified
earnings per share for 2009 (such date of certification being
referred to as the First Vesting Date), and the same
number of restricted shares that vested on the First Vesting
Date vests on both the first anniversary and the second
anniversary of the First Vesting Date so long as the executive
officer is employed by the Company on each such date (subject to
certain exceptions). In accordance with SEC rules, the target
number of achievable shares is shown above because in fiscal
year 2009, the Company exceeded the threshold modified earnings
per share specified in the award.
(15) Represents the target payout
of a performance-based restricted stock unit award made on
February 26, 2009, at $47.69, the Companys closing
stock price on December 31, 2009. In connection with the
awards of performance-based restricted stock units, the
Compensation Committee adopted as a performance goal a range of
improvement in modified earnings per share. If the
Companys 2009 modified EPS were equal to or greater than
$2.59, then the executives would be entitled to a number of
shares ranging from 60% to 160% of the target number of shares
granted. Modified EPS of $3.01 for 2009 led to an actual payout
of 94.29% of the target number of units for each executive.
One-third of the total number of units earned vested in February
2010, and the same number of restricted shares will vest on both
the first anniversary and the second anniversary of this vesting
date so long as the executive officer is employed by the Company
on each such date (subject to certain exceptions).
(16) Represents the balance of a
stock option granted on May 15, 2008, which vests in equal
annual installments on May 15, 2010 and 2011 so long as the
executive officer is employed by the Company on each such date
(subject to certain exceptions).
Page 29
(17) Represents the balance of a
stock option granted on July 10, 2008, which vests in equal
annual installments on July 10, 2010, 2011, 2012 and 2013,
so long as the executive officer is employed by the Company on
each such date (subject to certain exceptions).
(18) Represents the balance of a
stock option granted on July 10, 2008, which vests in equal
annual installments on July 10, 2010 and 2011, so long as
the executive officer is employed by the Company on each such
date (subject to certain exceptions).
Option
Exercises and Stock Vested During 2009
The following table reports information regarding stock option
exercises and the vesting of stock awards during fiscal year
2009 by the Companys named executive officers. No stock
appreciation rights were exercised or were outstanding during
fiscal year 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
Stock Awards
|
|
|
|
|
Number of
|
|
|
|
Value
|
|
|
|
Number of
|
|
|
|
Value
|
|
|
|
|
Shares
|
|
|
|
Realized
|
|
|
|
Shares
|
|
|
|
Realized
|
|
|
|
|
Acquired on
|
|
|
|
On
|
|
|
|
Acquired on
|
|
|
|
On
|
|
|
|
|
Exercise
|
|
|
|
Exercise
|
|
|
|
Vesting
|
|
|
|
Vesting
|
|
Name
|
|
|
(#)
|
|
|
|
($)(1)
|
|
|
|
(#)
|
|
|
|
($)(2)
|
|
Marc N. Casper
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,369
|
|
|
|
|
$879,375
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter M. Wilver
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,911
|
|
|
|
|
$512,274
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory J. Herrema
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,877
|
|
|
|
|
$262,677
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alan J. Malus
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,659
|
|
|
|
|
$852,890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Pesicka
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,421
|
|
|
|
|
$694,594
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marijn E. Dekkers
|
|
|
|
669,960
|
|
|
|
|
$5,424,661
|
|
|
|
|
15,133
|
|
|
|
|
$644,556
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) The amounts shown in this
column represent the difference between the option exercise
price and the market price on the date of exercise.
(2) The amounts shown in this
column represent the number of shares vesting multiplied by the
market price on the date of vesting.
Pension
Benefits
Prior to the merger of Thermo Electron Corporation and Fisher
Scientific International, Inc. (Fisher) (the
Fisher Merger), Fisher maintained the Fisher
Retirement Plan (which was renamed after the merger to the
Thermo Fisher Scientific Inc. Retirement Plan, or the
Retirement Plan), a broad-based,
U.S. tax-qualified cash balance pension plan.
Each month prior to January 1, 2006, Fisher credited each
participating employee with an amount equal to 3.5% of monthly
compensation, which included base salary plus certain annual
bonuses and other types of compensation.
The Retirement Plan credits participants monthly with interest
on their cash balances. The interest credit is equal to the
balance of the participants account as of the close of the
prior calendar month multiplied by the applicable interest rate.
The Retirement Plan sets the interest rate each year based on
the average of the interest rates for the thirty-year U.S.
Treasury Note over the
12-month
period ending during November of the preceding plan year. For
2009, the interest rate was 4.5%.
The Retirement Plan was amended, effective December 31,
2005, to discontinue future benefit accruals (other than
crediting interest to outstanding account balances) as of such
date. Accordingly, effective January 1, 2006, Fisher no
longer credited each participating employee with an amount equal
to 3.5% of the employees monthly compensation. However,
participants continue to earn interest on their previously
accrued benefit (account balance). Generally, all participants
who were employed as of January 1, 2006 became fully vested
in their accrued benefits under the Retirement Plan as of such
date. Vested participants can generally elect to receive their
benefits under the Retirement Plan after separation from service
in either a lump sum or an annuity.
Page 30
The table below shows the present value of accumulated benefits
payable to each of the named executive officers under the
Retirement Plan. As the Retirement Plan was a pension plan
maintained by Fisher prior to the Fisher Merger, and was frozen
prior to the merger, only Messrs. Malus and Pesicka (former
employees of Fisher) participate in the Retirement Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Years
|
|
|
|
Present Value of
|
|
|
|
Payments During
|
|
|
|
|
|
|
|
Credited Service
|
|
|
|
Accumulated Benefit
|
|
|
|
Last Fiscal Year
|
|
Name
|
|
|
Plan Name
|
|
|
(#)
|
|
|
|
($)(1)
|
|
|
|
($)
|
|
Marc N. Casper
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter M. Wilver
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory J. Herrema
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alan J. Malus
|
|
|
Thermo Fisher Scientific Inc. Retirement
Plan
|
|
|
|
11
|
|
|
|
$
|
54,256
|
|
|
|
|
|
|
Edward A. Pesicka
|
|
|
Thermo Fisher Scientific Inc. Retirement
Plan
|
|
|
|
10
|
|
|
|
$
|
40,523
|
|
|
|
|
|
|
Marijn E. Dekkers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Represents the actuarial
present value of accumulated benefit as of December 31,
2009 under the Retirement Plan, based on assumptions of a 5.5%
discount rate, a cash balance interest crediting rate of 4.5%,
and a retirement age of 65.
Nonqualified
Deferred Compensation For 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
|
|
|
Registrant
|
|
|
Aggregate
|
|
|
Aggregate
|
|
|
|
|
|
|
Contributions
|
|
|
Contributions
|
|
|
Earnings in
|
|
|
Withdrawals/
|
|
|
Aggregate Balance at
|
Name
|
|
|
in Last FY ($)(1)
|
|
|
in Last FY ($)(2)
|
|
|
Last FY ($)
|
|
|
Distributions ($)
|
|
|
Last FYE ($)(3)
|
Marc N. Casper
|
|
|
$
|
87,210
|
|
|
$77,770
|
|
|
$
|
159,966
|
|
|
|
|
|
$806,651(4)
|
Peter M. Wilver
|
|
|
$
|
87,683
|
|
|
$48,710
|
|
|
$
|
15,848
|
|
|
|
|
|
$158,114(5)
|
Gregory J. Herrema
|
|
|
$
|
167,743
|
|
|
$29,157
|
|
|
$
|
108,892
|
|
|
|
|
|
$770,980(6)
|
Alan J. Malus
|
|
|
$
|
231,854
|
|
|
$46,173
|
|
|
$
|
57,406
|
|
|
|
|
|
$513,071(7)
|
Edward A. Pesicka
|
|
|
$
|
126,800
|
|
|
$36,020
|
|
|
$
|
32,746
|
|
|
|
|
|
$160,951(8)
|
Marijn E. Dekkers
|
|
|
$
|
118,592
|
|
|
$39,537
|
|
|
$
|
691,871
|
|
|
$1,669,156
|
|
|
$1,364,052
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Represents deferral of a
portion of 2009 salary and/or bonus earned for 2009 performance.
This amount is also included in the Salary and/or
the Non-Equity Incentive Plan Compensation columns
in 2009 for the named executive officer in the Summary
Compensation Table on page 22.
(2) Represents a matching Company
contribution in the deferred compensation plan with respect to
2009 salary
and/or bonus
earned for 2009, which amount is also included, for each of the
named executive officers, in the All Other
Compensation column for 2009 in the Summary Compensation
Table on page 22.
(3) Includes, for all named
executive officers other than Mr. Dekkers, a matching
Company contribution payable in 2010 in the deferred
compensation plan with respect to bonus earned for 2009
performance.
(4) Of this amount, $71,000 was
withheld from Mr. Caspers bonus earned for 2008
performance for deferral and $37,738 was withheld from his 2009
salary for deferral, which amounts are also included in the
Non-Equity Incentive Plan Compensation and
Salary columns, respectively, for 2008 and 2009 for
Mr. Casper in the Summary Compensation Table on
page 22.
Page 31
(5) Of this amount, $60,683 was
withheld from Mr. Wilvers 2009 salary for deferral,
which amount is also included in the Salary column
for 2009 for Mr. Wilver in the Summary Compensation Table
on page 22.
(6) Of this amount, $22,833 was
withheld from Mr. Herremas 2009 salary for deferral,
which amount is also included in the Salary column
for 2009 for Mr. Herrema in the Summary Compensation Table
on page 22.
(7) Of this amount, $204,265 was
withheld from Mr. Malus 2009 salary for deferral and
$200,000 was withheld from his 2008 salary for deferral, which
amounts are also included in the Salary columns for
2009 and 2008, respectively for Mr. Malus in the Summary
Compensation Table on page 22.
(8) Of this amount, $68,836 was
withheld from Mr. Pesickas 2009 salary for deferral,
which amount is also included in the Salary column
for 2009 for Mr. Pesicka in the Summary Compensation Table
on page 22.
The Company maintains a deferred compensation plan for its
executive officers and certain other highly compensated
employees. Under the plan in effect for amounts deferred on or
after January 1, 2005 through December 31, 2008 (the
2005 Deferred Compensation Plan), a participant had
the right to defer receipt of his or her annual base salary (up
to 90%)
and/or
annual incentive bonus (up to 100%) until he or she ceased to
serve as an employee of the Company or until a future date while
the participant continued to be an employee of the Company. The
Company credited (or debited) a participants account with
the amount that would have been earned (or lost) had the
deferred amounts been invested in one or more of three different
funds that were available under the deferred compensation plan
(an equity index fund, a bond index fund, and a money market
fund) as selected by the participant. The participant did not
have any actual ownership in these funds. Any gains (or losses)
on amounts deferred are not taxable until deferred amounts are
paid to the participant. All amounts in the participants
deferred account represent unsecured obligations of the Company.
The 2005 Deferred Compensation Plan is intended to comply with
Section 409A of the Code as enacted under The American Jobs
Creation Act of 2004. The 2005 Deferred Compensation Plan
remains in existence and applies to amounts deferred between
January 1, 2005 and December 31, 2008. The Deferred
Compensation Plan that the Company adopted in 2001 (the
Original Deferred Compensation Plan) remains in
existence and applies to amounts deferred on or before
December 31, 2004. The Company has frozen the
terms of the Original Deferred Compensation Plan in existence as
of December 31, 2004 for account balances resulting from
amounts deferred through such date.
The Original Deferred Compensation Plan provides for the payout
of either all or a portion of the participants account
beginning (1) at a specified date in the future if the
participant so elects (in the case of a short-term payout),
(2) in the case of the participants death or
disability, or (3) upon the participants retirement
or termination from employment with the Company. In the case of
the participants death or disability, or upon the
participants termination, payment is made in a lump sum
distribution. Upon retirement, the participant may elect to
receive his or her distribution in a lump sum or in annual
installment payments over the course of five, ten or fifteen
years. Additionally, with respect to account balances existing
at December 31, 2004, the executive may receive a full or
partial payout from the plan for an unforeseeable financial
emergency (as defined in the plan), or may withdraw all of his
or her account at any time less a withdrawal penalty equal to
10% of such amount (haircut provision). The
distribution provisions of the 2005 Deferred Compensation Plan
are substantially similar to the provisions of the Original
Deferred Compensation Plan except that the 2005 Deferred
Compensation Plan does not permit haircut
distributions and the time and form of payment after retirement
must be elected at the time the participant makes his or her
initial deferral election.
During the year ended December 31, 2009, participants in
the Original Deferred Compensation Plan and the 2005 Deferred
Compensation Plan were given the opportunity to select among
several investment funds. The Original Deferred Compensation
Plan and the 2005 Deferred Compensation Plan allow the executive
to reallocate his or her balance and future deferrals among the
investment choices up to four times in any plan year. The table
below shows the funds available to participants and their annual
rate of return for the year ended December 31, 2009.
Page 32
|
|
|
|
|
|
Name of Fund
|
|
|
Rate of Return (assuming
reinvestment of dividends)
|
|
T. Rowe Price Retirement Income Fund
|
|
|
|
22.06%
|
|
T. Rowe Price Retirement 2005 Fund
|
|
|
|
24.55%
|
|
T. Rowe Price Retirement 2010 Fund
|
|
|
|
27.95%
|
|
T. Rowe Price Retirement 2015 Fund
|
|
|
|
31.35%
|
|
T. Rowe Price Retirement 2020 Fund
|
|
|
|
34.19%
|
|
T. Rowe Price Retirement 2025 Fund
|
|
|
|
36.29%
|
|
T. Rowe Price Retirement 2030 Fund
|
|
|
|
37.99%
|
|
T. Rowe Price Retirement 2035 Fund
|
|
|
|
39.04%
|
|
T. Rowe Price Retirement 2040 Fund
|
|
|
|
39.07%
|
|
T. Rowe Price Retirement 2045 Fund
|
|
|
|
39.10%
|
|
T. Rowe Price Retirement 2050 Fund
|
|
|
|
38.92%
|
|
T. Rowe Price Retirement 2055 Fund
|
|
|
|
38.97%
|
|
T. Rowe Price Stable Value Common Trust Fund
|
|
|
|
4.20%
|
|
Western Asset Core Plus Institutional
|
|
|
|
26.21%
|
|
Dodge & Cox Stock Fund
|
|
|
|
31.27%
|
|
SSgA S&P 500 Index C
|
|
|
|
28.49%
|
|
T. Rowe Price Growth Stock Trust
|
|
|
|
43.28%
|
|
Vanguard Mid Cap Index Institutional
|
|
|
|
40.51%
|
|
Jennison Institutional US Small Cap Equity
|
|
|
|
34.09%
|
|
Dodge & Cox International Stock
|
|
|
|
47.46%
|
|
|
|
|
|
|
|
In September 2008, the Compensation Committee approved the
Amended and Restated 2005 Deferred Compensation Plan, effective
January 1, 2009 (the Amended and Restated Deferred
Compensation Plan). Pursuant to the Amended and Restated
Deferred Compensation Plan, an eligible employee can defer
receipt of his or her annual base salary (up to 50%)
and/or bonus
(up to 50%) until he or she ceases to serve as an employee of
the Company or until a future date while the participant
continues to be an employee of the Company. Amounts deferred
under this plan can be invested in an array of mutual funds and
vehicles, administered by The Newport Group, which are similar
to the investment options available in the Companys 401(k)
Plan. The Amended and Restated Deferred Compensation Plan is
substantially similar to the original 2005 Deferred Compensation
Plan, except the Amended and Restated Deferred Compensation Plan
includes a Company match of 100% of the first 6% of pay that is
deferred into the Plan over the IRS annual compensation limit
for 401(k) purposes. In connection with the approval of the
Amended and Restated Deferred Compensation Plan, the
Companys Compensation Committee also approved a one-time
credit in the deferred compensation accounts of eligible plan
participants who did not elect to defer 6% of their 2008 bonus,
payable in March 2009. Code Section 409A effectively
prohibited these eligible participants from making deferrals of
the 2008 bonus in 2008. The one-time credit is equal to the 6%
match they would have received had they deferred 6% of their
March 2009 bonus payment. In order to receive this one-time
credit, eligible plan participants who did not elect to defer a
portion of their 2008 bonus and who are officers of the Company
were required to defer at least 6% of their 2009 salary to the
plan.
Page 33
Agreements
with Named Executive Officers; Potential Payments Upon
Termination or Change in Control
Employment,
Retention and Severance Agreements
Employment
Agreement with Mr. Dekkers
The amended and restated employment agreement with
Mr. Dekkers, which was executed on April 7, 2008 and
pursuant to which he served as president and chief executive
officer of the Company until his resignation from the Company on
September 15, 2009 (effective October 15, 2009) (the
Employment Agreement), was for a term ending
December 31, 2017. The Employment Agreement provided for an
annual base salary of $1,218,000 and a target annual incentive
bonus of 125% of base salary. The actual amount paid as a bonus
in any given year was a multiple of zero to two times the target
amount. The Employment Agreement provided that in the event
Mr. Dekkers employment was terminated by
Mr. Dekkers without good reason (as it
was due to his resignation from the Company), he would receive
his base salary through the date of termination and (A) no
further vesting of stock options would occur and he would have
90 days to exercise all vested and outstanding stock
options (except for one stock option grant made in 2000, as to
which he would have 60 days to exercise) (but in no event
beyond the expiration date of the options); and (B) all
shares of restricted Common Stock granted to him as to which
transfer restrictions had not lapsed would be forfeited.
The Employment Agreement includes a noncompetition and
nonsolicitation provision providing that during the term of
Mr. Dekkers employment with the Company, and for a
period of two years thereafter, Mr. Dekkers would not
compete with the Company, nor would he solicit or hire employees
of the Company or solicit customers of the Company.
Executive
Change in Control Retention Agreements
In May 2008, in connection with the expiration of its existing
change in control retention agreements with executives (other
than Mr. Dekkers), the Compensation Committee authorized
new executive change in control retention agreements with
executives that provide cash and other severance benefits if
there is a change in control of the Company and their employment
is terminated by the Company without cause or by the
individual for good reason, as those terms are
defined therein, in each case within 18 months thereafter.
For purposes of these agreements, a change in control exists
upon (i) the acquisition by any person of 50% or more of
the outstanding Common Stock or voting securities of Thermo
Fisher; (ii) the failure of the Board to include a majority
of directors who are continuing directors, which
term is defined to include directors who were members of the
Board on the date of the agreement or who subsequent to the date
of the agreement were nominated or elected by a majority of
directors who were continuing directors at the time
of such nomination or election; (iii) the consummation of a
merger, consolidation, reorganization, recapitalization or
statutory share exchange involving Thermo Fisher or the sale or
other disposition of all or substantially all of the assets of
Thermo Fisher unless immediately after such transaction:
(a) all holders of Common Stock immediately prior to such
transaction own more than 50% of the outstanding voting
securities of the resulting or acquiring corporation in
substantially the same proportions as their ownership
immediately prior to such transaction and (b) no person
after the transaction owns 50% or more of the outstanding voting
securities of the resulting or acquiring corporation; or
(iv) approval by stockholders of a complete liquidation or
dissolution of Thermo Fisher.
The 2008 executive change in control retention agreements with
Messrs. Wilver, Herrema, Malus and Pesicka provide that,
upon a qualifying termination, the executive would be entitled
to (A) a lump sum payment equal to (1) two multiplied
by (2) the sum of (x) the higher of the
executives annual base salary as in effect immediately
prior to the measurement date or the
termination date, as those terms are defined
therein, and (y) the higher of the executives target
bonus as in effect immediately prior to the measurement date or
the termination date, and (B) a pro rata bonus for the year
of termination, based on the higher of the executives
target bonus as in effect immediately prior to the measurement
date or the termination date. In addition, the executive would
be provided continuing medical, dental and life insurance
benefits for a period of two years, after such termination. The
Company would also provide outplacement services through an
outside firm to the executive up to an aggregate of $20,000.
Page 34
The expired executive change in control agreements with
Messrs. Wilver, Herrema, Malus and Pesicka contained a tax
gross-up
payment in the event that total payments exceeded the maximum
amount allowable without being treated as so-called excess
parachute payments under the applicable provisions of the
Code. The 2008 agreements contain a modified
gross-up
provision, such that the executive does not receive a tax
gross-up
unless the total payments exceed 110% of the maximum amount
allowable without being treated as excess parachute payments
under the Code. In the event that the total payments under the
2008 agreements are between 100% and 110% of the maximum amount
of total payments the executive could receive without being
treated as receiving any excess parachute payments, the
executives payments will be cutback so that
the total payments he receives will not cause him to be treated
as receiving any excess parachute payments.
In February 2009, the Companys Compensation Committee
approved a new form of executive change in control agreement for
executives joining the Company after February 2009. The new form
of change in control agreement eliminated any tax
gross-up
provision, as the Company does not intend to extend tax
gross-ups in
future compensation arrangements.
In November 2009, in connection with his appointment as
President and Chief Executive Officer of the Company,
Mr. Casper signed a new change in control agreement that
was substantially similar to his old agreement. The agreement
provides that, upon a qualifying termination, he would be
entitled to (A) a lump sum payment equal to (1) two
multiplied by (2) the sum of (x) the higher of
Mr. Caspers annual base salary as in effect
immediately prior to the change in control date or
the date of termination, as those terms are defined
therein, and (y) the higher of Mr. Caspers
target bonus as in effect immediately prior to the change in
control date or the date of termination, and (B) a pro rata
bonus for the year of termination, based on the higher of
Mr. Caspers target bonus as in effect immediately
prior to the change in control date or the date of termination.
In addition, Mr. Casper would be provided continuing
medical, dental and life insurance benefits for a period of two
years, after such termination. The Company would also provide
outplacement services through an outside firm to Mr. Casper
up to an aggregate of $20,000. Mr. Caspers new change
in control agreement with the Company provides that he would not
receive any tax
gross-up
payment (or modified tax
gross-up
payment) in the event that total payments exceeded the maximum
amount allowable without being treated as excess parachute
payments under the Code.
Executive
Severance Policy
The Company maintains an executive severance policy for
executives that provides that, in the event an executive
officers employment is terminated by the Company without
cause (as such term is defined therein), he would be
entitled to a lump sum severance payment equal to the sum of
(A) 1.5 times his annual base salary then in effect, and
(B) 1.5 times his target bonus for the year in which the
date of termination occurs, except that if the executive
receives benefits under the executive change in control
retention agreement described above, he would not be entitled to
also receive benefits under the executive severance policy. In
addition, for 18 months after the date of termination, the
executive would be provided medical, dental and life insurance
benefits at least equal to those he would have received had his
employment not been terminated, or if more favorable, to those
in effect generally during such period with respect to peer
executives of the Company. Finally, the executive would be
entitled to up to $20,000 of outplacement services until the
earlier of 12 months following his termination or the date
he secures full-time employment. Messrs. Wilver, Herrema,
Malus, and Pesicka are eligible to receive benefits under the
Companys executive severance policy.
In February 2010, the Company adopted an amendment to the
executive severance policy in order to comply with a recent
Internal Revenue Service ruling. The Company adopted the
amendment in order to preserve the tax deductibility of the
Companys annual performance-bonuses to executive officers.
The amendment provides that an executive officer who is
terminated during the year without cause (as defined
in the policy) would receive, in addition to the amounts
described above, a pro rata bonus for that year, based on his or
her target bonus. That pro rata bonus would not be paid until
March of the following year, when the other officer bonuses
would be paid, and only if the performance goals established
pursuant to the Companys 2008 Annual Incentive Award Plan
(or similar provision of any applicable shareholder-approved
successor plan) applicable to the other officers were met.
Page 35
Executive
Severance Agreement
In November 2009, in connection with his appointment as
President and Chief Executive Officer of the Company,
Mr. Casper signed a restated executive severance agreement
with the Company. The agreement provides that, in the event his
employment is terminated by the Company without
cause or by him for good reason (as such
terms are defined therein), he would be entitled to a lump sum
severance payment equal to the sum of (A) two
(2) times his annual base salary then in effect, and
(B) two (2) times his target bonus for the year in
which the date of termination occurs, except that if
Mr. Casper receives benefits under his executive change in
control retention agreement described above, he would not be
entitled to also receive benefits under his executive severance
agreement. In addition, for two years after the date of
termination, Mr. Casper would be provided medical, dental
and life insurance benefits at least equal to those he would
have received had his employment not been terminated, or if more
favorable, to those in effect generally during such period with
respect to peer executives of the Company. Finally,
Mr. Casper would be entitled to up to $20,000 of
outplacement services until the earlier of 12 months
following his termination or the date he secures full-time
employment.
In February 2010, the Company and Mr. Casper also amended
Mr. Caspers severance agreement in order to comply
with the Internal Revenue Service ruling referred to above,
providing that, in the case of involuntary termination without
cause or good reason termination of his
employment (as each of those terms is defined in his agreement),
Mr. Casper would only receive his pro rata bonus for the
year of termination if the performance goals established
pursuant to the Companys 2008 Annual Incentive Award Plan
(or similar provision of any applicable shareholder-approved
successor plan) applicable to the other officers were met, and
that pro rata bonus would not be paid until March of the
following year, when the other officer bonuses would be paid.
Treatment
of Equity
Upon death, disability, or a qualifying retirement of
Messrs. Wilver, Herrema, Malus and Pesicka, outstanding
stock options and time-based restricted stock awards and
restricted stock unit awards will vest (except, in the case of a
qualifying retirement, for performance-based restricted stock
awards granted to Messrs. Wilver and Malus on
November 9, 2006, which, once the performance conditions
were met, became time-based vesting). In the event of an
executive officers termination by the Company without
cause or by the individual for good
reason, as those terms are defined in the executive change
in control agreements, within 18 months of a qualifying
change in control, each outstanding stock option and time-based
restricted stock award granted to an executive officer on or
after November 9, 2006 will vest.
In the case of Mr. Casper, in the event he is terminated
without cause or he leaves voluntarily for
good reason, as those terms are defined in his
severance agreement, both performance-based restricted stock
awards (which, once the performance conditions were met, became
time-based vesting), and stock options, granted on
November 9, 2006, stock options granted on May 15,
2008, and certain tranches of stock options and time-based
restricted stock units granted on November 21, 2009, will
vest, and performance-based restricted stock units granted on
November 21, 2009, associated with the then current
measurement period, will vest if the applicable performance
conditions are eventually met. In the event he is terminated
without cause or he leaves voluntarily for
good reason within 18 months of a qualifying
change in control, as those terms are defined in his executive
change in control agreement, performance-based restricted stock
awards granted on November 9, 2006 and March 5, 2008
(both of which, once the performance conditions were met, became
time-based vesting), stock options granted on November 9,
2006 and May 15, 2008, time-based restricted stock awards
granted on March 5, 2008 and November 21, 2009, and
time-based stock options granted on November 21, 2009 will
vest, and performance-based restricted stock units granted on
November 21, 2009, associated with the then-current
measurement period, will vest if the applicable performance
conditions are met at the time of the change in control. Upon
his death or disability, performance-based restricted stock
awards granted on November 9, 2006 and March 5, 2008
(both of which, once the performance conditions were met, became
time-based vesting), stock options granted on November 9,
2006 and May 15, 2008, time-based restricted stock awards
granted on March 5, 2008, time-based stock options granted
on November 21, 2009, and fifty percent (50%) of time-based
restricted stock awards granted on November 21, 2009, will
vest,
Page 36
and performance-based restricted stock units granted on
November 21, 2009, associated with the then-current
measurement period, will vest at target.
Noncompetition
Agreements
The Company has entered into noncompetition agreements with its
executive officers and certain key employees, other than
Mr. Dekkers, whose employment agreement also includes
noncompetition and nonsolicitation provisions. See
Agreements with Named Executive Officers; Potential
Payments Upon Termination or Change in Control on
page 33. The terms of the noncompetition agreement provide
that during the term of the employees employment with the
Company, and for a period of eighteen (18) months in the
case of Messrs. Wilver, Herrema, Malus and Pesicka, and
twenty-four (24) months in the case of Mr. Casper,
thereafter, the employee will not compete with the Company. The
agreement also contains provisions that restrict the
employees ability during the term of the employees
employment with the Company and for a period of eighteen
(18) months after termination (or twenty-four
(24) months in the case of Mr. Casper), to solicit or
hire employees of the Company or to solicit customers of the
Company.
Tables
The tables below reflect the amount of compensation payable to
each of the named executive officers of the Company in the event
of termination of such executives employment or a change
in control of the Company. The amount of compensation payable to
each named executive officer upon voluntary resignation,
involuntary termination for cause, involuntary termination
without cause or voluntarily for good reason, involuntary
termination without cause or voluntarily for good reason within
18 months of a change in control, upon a change in control
without termination, and in the event of disability or death of
the executive is shown below. The amounts shown assume that such
termination was effective as of December 31, 2009, and thus
include amounts earned through such time and are estimates of
the amounts which would be paid out to the executives upon such
event. The actual amounts to be paid out can only be determined
at the time of such event.
Marijn Dekkers resigned as President and Chief Executive Officer
and from the Board of Directors of the Company, effective
October 15, 2009. Mr. Dekkers employment was
terminated by Mr. Dekkers without good reason
as defined in his Employment Agreement, and therefore upon his
departure he was entitled only to his base salary through the
date of termination, shares of restricted stock that were vested
as of the date of his termination, and the right to exercise
stock options that were vested through the date of his
termination for a period of 90 days (except for one stock
option grant made in 2000, as to which he would have
60 days to exercise).
Page 37
Marc N.
Casper
The following table shows the potential payments upon
termination or a change in control of the Company for Marc
Casper, the Companys President and Chief Executive Officer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resignation
|
|
|
|
|
|
Involuntary
|
|
|
Without Cause or
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without
|
|
|
|
|
|
Without Cause or
|
|
|
by Executive for
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good
|
|
|
Involuntary
|
|
|
by Executive for
|
|
|
Good Reason
|
|
|
CIC Without
|
|
|
|
|
|
|
|
|
|
|
|
Reason
|
|
|
For Cause
|
|
|
Good Reason
|
|
|
(with CIC)
|
|
|
Termination
|
|
|
Disability
|
|
|
Death
|
|
|
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
|
INCREMENTAL BENEFITS DUE TO TERMINATION EVENT OR CHANGE IN
CONTROL
|
Cash Severance
|
Base Salary
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,860,000
|
|
|
|
$1,860,000
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Bonus
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,649,066
|
|
|
|
$1,649,066
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Pro-rata Bonus
|
|
|
$824,533
|
(2)
|
|
|
$0
|
|
|
|
$823,266
|
(3)
|
|
|
$824,533
|
(4)
|
|
|
$0
|
|
|
|
$823,266
|
(3)
|
|
|
$823,266
|
(3)
|
|
|
|
|
|
Total Cash Severance
|
|
|
$824,533
|
|
|
|
$0
|
|
|
|
$4,332,332
|
|
|
|
$4,333,599
|
|
|
|
$0
|
|
|
|
$823,266
|
|
|
|
$823,266
|
|
|
|
Benefits & Perquisites
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(5)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$53,179
|
|
|
|
$53,179
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Outplacement
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,000
|
|
|
|
$20,000
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
Total Benefits & Perquisites
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$73,179
|
|
|
|
$73,179
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
280G Tax
Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
$N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain of Accelerated Stock Options
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$570,883
|
|
|
|
$1,113,283
|
|
|
|
$0
|
|
|
|
$1,113,283
|
|
|
|
$1,113,283
|
|
|
|
Value of Accelerated Restricted Stock(6)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$2,642,026
|
|
|
|
$10,631,913
|
|
|
|
$0
|
|
|
|
$5,862,913
|
|
|
|
$5,862,913
|
|
|
|
Value of Accelerated Performance Restricted Stock and Units
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$2,384,500
|
|
|
|
$2,384,500
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$3,212,909
|
|
|
|
$11,745,196
|
|
|
|
$0
|
|
|
|
$9,360,696
|
|
|
|
$9,360,696
|
|
|
|
|
|
|
Total Value: Incremental Benefits
|
|
|
$824,533
|
|
|
|
$0
|
|
|
|
$7,618,420
|
|
|
|
$16,151,974
|
|
|
|
$0
|
|
|
|
$10,183,962
|
|
|
|
$10,183,962
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) In all termination scenarios,
the named executive officer retains vested amounts in the
Companys deferred compensation plan. These amounts are
described in the Aggregate Balance at Last FYE
column of the Nonqualified Deferred Compensation table on
page 30.
(2) Represents an assumed target
bonus award for 2009.
(3) Represents target bonus for
2009.
(4) Represents bonus paid in 2009
for 2008 performance.
(5) Includes for the two-year
period (a) premiums of $24,965 with respect to medical and
dental insurance, and (b) premiums of $28,251 paid by the
Company for life insurance.
(6) Based on the closing price of
the Companys Common Stock on the New York Stock Exchange
on December 31, 2009 of $47.69.
Page 38
Gregory
J. Herrema
The following table shows the potential payments upon
termination or a change in control of the Company for Gregory
Herrema, the Companys Senior Vice President.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary
|
|
|
|
|
|
Without
|
|
|
Cause or by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resignation
|
|
|
|
|
|
Cause or by
|
|
|
Executive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without
|
|
|
|
|
|
Executive
|
|
|
for Good
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good
|
|
|
Involuntary
|
|
|
for Good
|
|
|
Reason
|
|
|
CIC Without
|
|
|
|
|
|
|
|
|
|
|
|
Reason
|
|
|
For Cause
|
|
|
Reason
|
|
|
(with CIC)
|
|
|
Termination
|
|
|
Disability
|
|
|
Death
|
|
|
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
|
INCREMENTAL BENEFITS DUE TO TERMINATION EVENT OR CHANGE IN
CONTROL
|
Cash Severance
|
Base Salary
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$690,045
|
|
|
|
$920,060
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Bonus
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$483,032
|
|
|
|
$644,042
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Pro-rata Bonus
|
|
|
$322,021
|
(2)
|
|
|
$0
|
|
|
|
$322,021
|
(3)
|
|
|
$322,021
|
(3)
|
|
|
$0
|
|
|
|
$322,021
|
(2)
|
|
|
$322,021
|
(2)
|
|
|
|
|
|
Total Cash Severance
|
|
|
$322,021
|
|
|
|
$0
|
|
|
|
$1,495,098
|
|
|
|
$1,886,123
|
|
|
|
$0
|
|
|
|
$322,021
|
|
|
|
$322,021
|
|
|
|
Benefits & Perquisites
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$21,103
|
(4)
|
|
|
$28,523
|
(5)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Outplacement
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,000
|
|
|
|
$20,000
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
Total Benefits & Perquisites
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$41,103
|
|
|
|
$48,523
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
280G Tax
Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain of Accelerated Stock Options
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,048,670
|
|
|
|
$0
|
|
|
|
$1,048,670
|
|
|
|
$1,048,670
|
|
|
|
Value of Accelerated Restricted Stock(6)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,333,126
|
|
|
|
$0
|
|
|
|
$1,333,126
|
|
|
|
$1,333,126
|
|
|
|
Value of Accelerated Performance Restricted Stock and Units
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$2,381,796
|
|
|
|
$0
|
|
|
|
$2,381,796
|
|
|
|
$2,381,796
|
|
|
|
|
|
|
Total Value: Incremental Benefits
|
|
|
$322,021
|
|
|
|
$0
|
|
|
|
$1,536,200
|
|
|
|
$4,316,442
|
|
|
|
$0
|
|
|
|
$2,703,817
|
|
|
|
$2,703,817
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) In all termination scenarios,
the named executive officer retains vested amounts in the
Companys deferred compensation plan. These amounts are
described in the Aggregate Balance at Last FYE
column of the Nonqualified Deferred Compensation table on
page 30.
(2) Represents an assumed target
bonus award for 2009.
(3) Represents target bonus for
2009.
(4) Includes for the 1.5 year
period (a) premiums of $18,808 with respect to medical and
dental insurance, and (b) premiums of $2,295 paid by the
Company for life insurance.
(5) Includes for the two-year
period (a) premiums of $25,464 with respect to medical and
dental insurance, and (b) premiums of $3,059 paid by
the Company for life insurance.
(6) Based on the closing price of
the Companys Common Stock on the New York Stock Exchange
on December 31, 2009 of $47.69.
Page 39
Alan J.
Malus
The following table shows the potential payments upon
termination or a change in control of the Company for Alan
Malus, the Companys Senior Vice President.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary
|
|
|
|
|
|
Without
|
|
|
Cause or by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resignation
|
|
|
|
|
|
Cause or by
|
|
|
Executive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without
|
|
|
|
|
|
Executive
|
|
|
for Good
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good
|
|
|
Involuntary
|
|
|
for Good
|
|
|
Reason
|
|
|
CIC Without
|
|
|
|
|
|
|
|
|
|
|
|
Reason
|
|
|
For Cause
|
|
|
Reason
|
|
|
(with CIC)
|
|
|
Termination
|
|
|
Disability
|
|
|
Death
|
|
|
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
|
INCREMENTAL BENEFITS DUE TO TERMINATION EVENT OR CHANGE IN
CONTROL
|
Cash Severance
|
Base Salary
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$821,115
|
|
|
|
$1,094,820
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Bonus
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$574,781
|
|
|
|
$766,374
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Pro-rata Bonus
|
|
|
$383,187
|
(2)
|
|
|
$0
|
|
|
|
$383,187
|
(3)
|
|
|
$383,187
|
(3)
|
|
|
$0
|
|
|
|
$383,187
|
(2)
|
|
|
$383,187
|
(2)
|
|
|
|
|
|
Total Cash Severance
|
|
|
$383,187
|
|
|
|
$0
|
|
|
|
$1,779,083
|
|
|
|
$2,244,381
|
|
|
|
$0
|
|
|
|
$383,187
|
|
|
|
$383,187
|
|
|
|
Benefits & Perquisites
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$19,787
|
(4)
|
|
|
$26,746
|
(5)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Outplacement
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,000
|
|
|
|
$20,000
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
Total Benefits & Perquisites
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$39,787
|
|
|
|
$46,746
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
280G Tax
Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain of Accelerated Stock Options
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,196,932
|
|
|
|
$0
|
|
|
|
$1,196,932
|
|
|
|
$1,196,932
|
|
|
|
Value of Accelerated Restricted Stock(6)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$154,993
|
|
|
|
$1,668,959
|
|
|
|
$0
|
|
|
|
$1,668,959
|
|
|
|
$1,668,959
|
|
|
|
Value of Accelerated Performance Restricted Stock and Units
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$154,993
|
|
|
|
$2,865,891
|
|
|
|
$0
|
|
|
|
$2,865,891
|
|
|
|
$2,865,891
|
|
|
|
|
|
|
Total Value: Incremental Benefits
|
|
|
$383,187
|
|
|
|
$0
|
|
|
|
$1,973,862
|
|
|
|
$5,157,019
|
|
|
|
$0
|
|
|
|
$3,249,078
|
|
|
|
$3,249,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) In all termination scenarios,
the named executive officer retains vested amounts in the Fisher
Retirement Plan and the Companys deferred compensation
plan. These amounts are described under Pension
Benefits, and in the Aggregate Balance at Last
FYE column of the Nonqualified Deferred Compensation
table, respectively, on pages 29 and 30.
(2) Represents an assumed target
bonus award for 2009.
(3) Represents target bonus for
2009.
(4) Includes for the 1.5 year
period (a) premiums of $17,076 with respect to medical and
dental insurance, and (b) premiums of $2,711 paid by the
Company for life insurance.
(5) Includes for the two-year
period (a) premiums of $23,131 with respect to medical and
dental insurance, and (b) premiums of $3,615 paid by the
Company for life insurance.
(6) Based on the closing price of
the Companys Common Stock on the New York Stock Exchange
on December 31, 2009 of $47.69.
Page 40
Edward A.
Pesicka
The following table shows the potential payments upon
termination or a change in control of the Company for Edward
Pesicka, the Companys Senior Vice President.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary
|
|
|
|
|
|
Without
|
|
|
Cause or by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resignation
|
|
|
|
|
|
Cause or by
|
|
|
Executive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without
|
|
|
|
|
|
Executive
|
|
|
for Good
|
|
|
CIC
|
|
|
|
|
|
|
|
|
|
|
|
Good
|
|
|
Involuntary
|
|
|
for Good
|
|
|
Reason
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
|
|
Reason
|
|
|
For Cause
|
|
|
Reason
|
|
|
(with CIC)
|
|
|
Termination
|
|
|
Disability
|
|
|
Death
|
|
|
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
|
INCREMENTAL BENEFITS DUE TO TERMINATION EVENT OR CHANGE IN
CONTROL
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$690,045
|
|
|
|
$920,060
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Bonus
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$483,032
|
|
|
|
$644,042
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Pro-rata Bonus
|
|
|
$322,021
|
(2)
|
|
|
$0
|
|
|
|
$322,021
|
(3)
|
|
|
$322,021
|
(3)
|
|
|
$0
|
|
|
|
$322,021
|
(2)
|
|
|
$322,021
|
(2)
|
|
|
|
|
|
Total Cash Severance
|
|
|
$322,021
|
|
|
|
$0
|
|
|
|
$1,495,098
|
|
|
|
$1,886,123
|
|
|
|
$0
|
|
|
|
$322,021
|
|
|
|
$322,021
|
|
|
|
Benefits & Perquisites
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,704
|
(4)
|
|
|
$27,983
|
(5)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
Outplacement
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,000
|
|
|
|
$20,000
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
Total Benefits & Perquisites
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$40,704
|
|
|
|
$47,983
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
280G Tax
Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain of Accelerated Stock Options
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,074,935
|
|
|
|
$0
|
|
|
|
$1,074,935
|
|
|
|
$1,074,935
|
|
|
|
Value of Accelerated Restricted Stock(6)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,318,104
|
|
|
|
$0
|
|
|
|
$1,318,104
|
|
|
|
$1,318,104
|
|
|
|
Value of Accelerated Performance Restricted Stock and Units
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$2,393,039
|
|
|
|
$0
|
|
|
|
$2,393,039
|
|
|
|
$2,393,039
|
|
|
|
|
|
|
Total Value: Incremental Benefits
|
|
|
$322,021
|
|
|
|
$0
|
|
|
|
$1,535,801
|
|
|
|
$4,327,145
|
|
|
|
$0
|
|
|
|
$2,715,060
|
|
|
|
$2,715,060
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) In all termination scenarios,
the named executive officer retains vested amounts in the Fisher
Retirement Plan and the Companys deferred compensation
plan. These amounts are described under Pension
Benefits, and in the Aggregate Balance at Last
FYE column of the Nonqualified Deferred Compensation
table, respectively, on pages 29 and 30.
(2) Represents an assumed target
bonus award for 2009.
(3) Represents target bonus for
2009.
(4) Includes for the 1.5 year
period (a) premiums of $18,440 with respect to medical and
dental insurance, and (b) premiums of $2,264 paid by the
Company for life insurance.
(5) Includes for the two-year
period (a) premiums of $24,965 with respect to medical and
dental insurance, and (b) premiums of $3,018 paid by the
Company for life insurance.
(6) Based on the closing price of
the Companys Common Stock on the New York Stock Exchange
on December 31, 2009 of $47.69.
Page 41
Peter M.
Wilver
The following table shows the potential payments upon
termination or a change in control of the Company for Peter
Wilver, the Companys Senior Vice President and Chief
Financial Officer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary
|
|
|
|
|
|
Without
|
|
|
Cause or by
|
|
|
|
|
|
|
|
|
|
|
|
|
Resignation
|
|
|
|
|
|
Cause or by
|
|
|
Executive
|
|
|
|
|
|
|
|
|
|
|
|
|
Without
|
|
|
|
|
|
Executive
|
|
|
for Good
|
|
|
CIC
|
|
|
|
|
|
|
|
|
|
Good
|
|
|
Involuntary
|
|
|
for Good
|
|
|
Reason
|
|
|
Without
|
|
|
|
|
|
|
|
|
|
Reason
|
|
|
For Cause
|
|
|
Reason
|
|
|
(with CIC)
|
|
|
Termination
|
|
|
Disability
|
|
|
Death
|
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
|
12/31/09
|
|
|
12/31/09(1)
|
|
|
12/31/09(1)
|
|
INCREMENTAL BENEFITS DUE TO TERMINATION EVENT OR CHANGE IN
CONTROL
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$900,000
|
|
|
|
$1,200,000
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
Bonus
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$675,000
|
|
|
|
$900,000
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
Pro-rata Bonus
|
|
|
$450,000
|
(2)
|
|
|
$0
|
|
|
|
$450,000
|
(3)
|
|
|
$450,000
|
(3)
|
|
|
$0
|
|
|
|
$450,000
|
(2)
|
|
|
$450,000
|
(2)
|
|
|
|
Total Cash Severance
|
|
|
$450,000
|
|
|
|
$0
|
|
|
|
$2,025,000
|
|
|
|
$2,550,000
|
|
|
|
$0
|
|
|
|
$450,000
|
|
|
|
$450,000
|
|
Benefits & Perquisites
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$13,776
|
(4)
|
|
|
$18,587
|
(5)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
Outplacement
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$20,000
|
|
|
|
$20,000
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
Total Benefits & Perquisites
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$33,776
|
|
|
|
$38,587
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
280G Tax
Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain of Accelerated Stock Options
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$1,005,059
|
|
|
|
$0
|
|
|
|
$1,005,059
|
|
|
|
$1,005,059
|
|
Value of Accelerated Restricted Stock(6)
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$115,362
|
|
|
|
$1,552,596
|
|
|
|
$0
|
|
|
|
$1,552,596
|
|
|
|
$1,552,596
|
|
Value of Accelerated Performance Restricted Stock and Units
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$0
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
$0
|
|
|
|
$0
|
|
|
|
$115,362
|
|
|
|
$2,557,655
|
|
|
|
$0
|
|
|
|
$2,557,655
|
|
|
|
$2,557,655
|
|
|
|
|
Total Value: Incremental Benefits
|
|
|
$450,000
|
|
|
|
$0
|
|
|
|
$2,174,138
|
|
|
|
$5,146,242
|
|
|
|
$0
|
|
|
|
$3,007,655
|
|
|
|
$3,007,655
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) In all termination scenarios,
the named executive officer retains vested amounts in the
Companys deferred compensation plan. These amounts are
described in the Aggregate Balance at Last FYE
column of the Nonqualified Deferred Compensation table on
page 30.
(2) Represents an assumed target
bonus award for 2009.
(3) Represents target bonus for
2009.
(4) Includes for the 1.5 year
period (a) premiums of $10,785 with respect to medical and
dental insurance, and (b) premiums of $2,991 paid by the
Company for life insurance.
(5) Includes for the two-year
period (a) premiums of $14,599 with respect to medical and
dental insurance, and (b) premiums of $3,988 paid by the
Company for life insurance.
(6) Based on the closing price of
the Companys Common Stock on the New York Stock Exchange
on December 31, 2009 of $47.69.
Page 42
DIRECTOR
COMPENSATION
The Compensation Committee periodically reviews director
compensation and makes recommendations to the Board for changes
when deemed appropriate. The Board then acts on any such
recommendation by the Compensation Committee.
Cash
Compensation
During 2009, each non-management director (except
Mr. Manzi) received an annual retainer of $70,000. If a
Board committee met more than six times during a calendar year,
then the members thereof received an additional per committee
meeting fee, for meetings attended in excess of six ($1,500 per
committee meeting attended in person occurring on a day other
than a day on which the Board meets; $1,000 per committee
meeting attended in person occurring on the same day as a Board
meeting; $750 per committee meeting attended by means of
conference telephone).
The chairpersons of each of the Audit, Compensation, and
Nominating and Corporate Governance Committees, as well as the
chairpersons of the Strategy and Finance Committee of the Board
(the Strategy Committee), which committee consists
of Ms. Lewent (Chair), Messrs. Casper and Kaufman and
Drs. Porter and Jacks, and the Corporate Social
Responsibility Committee of the Board, which Committee consists
of Ms. Ullian (Chair), Mr. Bell, Ms. Lewent and
Mr. Parrett, receive additional compensation for their
services in those positions. The chairman of the Audit Committee
receives an additional annual retainer of $20,000, the chairman
of the Compensation Committee receives an additional annual
retainer of $10,000, and, during 2009, the chairpersons of each
of the Nominating and Corporate Governance, Strategy and
Corporate Social Responsibility Committees received an
additional annual retainer of $5,000. In addition, if the Board
elects a Presiding Director, that person receives an additional
annual retainer of $3,000.
Mr. Manzi serves as Chairman of the Board. As Chairman of
the Board, Mr. Manzi receives an annual retainer of
$250,000 (in lieu of the annual retainer and fees described
above). Mr. Casper, as an employee of the Company, receives
no additional compensation from the Company for service as a
director. Mr. Dekkers served as a director of the Company
through October 15, 2009, and as an employee of the
Company, received no additional compensation from the Company
for his service as a director. Payment of the annual retainers
and fees during 2009 were made quarterly. Directors are
reimbursed for
out-of-pocket
expenses incurred in attending Board and committee meetings.
Effective February 26, 2010, each non-management director
will receive an annual retainer of $80,000, and meeting fees
were eliminated. Additionally, the chairpersons of the
Nominating and Corporate Governance, Strategy and Corporate
Social Responsibility Committees will each receive an additional
annual retainer of $10,000 (increased from the $5,000 they
received in 2009).
Deferred
Compensation Plans for Directors
The Company maintains a deferred compensation plan for its
non-management directors (the Directors Deferred
Compensation Plan). Under the Directors Deferred
Compensation Plan, a participant may elect to defer receipt of
his or her annual retainer and meeting fees (if applicable).
Amounts deferred under the Directors Deferred Compensation Plan
are valued at the end of each quarter as units of Common Stock
and, when payable under the plan, may only be paid in shares of
Common Stock. Additional credits are made to a
participants account for cash and stock dividends that he
or she would have received had the participant been the owner of
such Common Stock on the record dates for payment of such
dividends. The Common Stock and cash credited to a
participants account are paid to the participant within
60 days after the end of the fiscal year in which the
participant ceases to serve as a director unless the participant
makes a timely election to defer the distribution in accordance
with the requirements of Section 409A of the Code. The
participant does not have any actual ownership of the Common
Stock until the Common Stock is distributed to the participant.
As of December 31, 2009, a total of 286,262 shares of
Common Stock were available for issuance under the Directors
Deferred Compensation Plan, of which deferred units equal to
13,836 shares of Common Stock were accumulated.
Page 43
Prior to the Fisher Merger, Fisher maintained a Deferred
Compensation Plan for non-employee directors of Fisher, pursuant
to which they could elect to have all or any portion of
compensation credited to a deferred compensation account.
Amounts credited to the directors account accrue interest
based upon the average quoted rate for
10-year
U.S. Treasury Notes. Deferred amounts are paid in a lump
sum or in installments commencing on the first business day of
the calendar year following the year in which the director
ceases to serve on the board of directors of Fisher or of a
later calendar year specified by the director. Prior to the
Fisher Merger, during his service on the Fisher board of
directors, Mr. Sperling had deferred amounts under this
plan. On January 2, 2009, Mr. Sperling received a
final payment of $61,626, after which he had no balance in his
account.
Fisher
Retirement Plan for Non-Employee Directors
Fisher maintained a Retirement Plan for non-employee directors,
pursuant to which a director who retires from the board of
directors with at least five years of service is eligible to
receive an annual retirement benefit for the remainder of the
directors lifetime and his or her spouses lifetime.
The annual retirement benefit for a director who retires with
five years of service is equal to 50% of the directors fee
in effect at the date of the directors retirement from the
Fisher board. For directors with more than five years of
service, the annual benefit is increased by 10% of the
directors fee in effect at the date of the directors
retirement for each additional year of service, up to 100% of
such fee for 10 or more years of service as a director. The
Fisher Merger resulted in a termination of service from the
Fisher board for Mr. Sperling, which resulted in the
commencement of the payout of benefits under the Retirement
Plan. Mr. Sperlings annual benefit is equal to 80% of
his then directors fee. Mr. Sperling receives a
quarterly payment under this plan of $12,000.
Stock-Based
Compensation
Non-management directors currently receive annual grants of
shares of Common Stock with a value of $125,000 based on the
closing price of the stock on the date of grant. In May 2009
each non-management director on the Board at that time received
a grant of 3,540 shares of Common Stock. New non-management
directors currently receive an initial option grant upon
election to the Board.
Matching
Charitable Donation Program
The Company has a matching charitable donation program for
independent directors, pursuant to which the Company matches
donations made by a director to a charity selected by the
director, up to $10,000 per director per year.
Page 44
Summary
Director Compensation Table
The following table sets forth a summary of the compensation of
the Companys non-employee directors for 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
|
|
|
Fees
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
Earned or
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
All Other
|
|
|
|
|
|
|
Paid in
|
|
|
|
Stock
|
|
|
Option
|
|
|
|
Compensation
|
|
|
Compensation
|
|
|
|
Name
|
|
|
Cash($)
|
|
|
|
Awards($)(1)
|
|
|
Awards($)(1)
|
|
|
|
Earnings
|
|
|
($)(2)
|
|
|
Total ($)
|
Michael A. Bell
|
|
|
|
$70,000
|
(3)
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$195,033
|
Tyler Jacks(4)
|
|
|
|
$45,558
|
|
|
|
|
|
|
|
$80,550
|
|
|
|
|
|
|
|
|
|
$126,108
|
Stephen P. Kaufman
|
|
|
|
$87,250
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
$10,000
|
|
|
$222,283
|
Judy C. Lewent
|
|
|
|
$70,664
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
$10,000
|
|
|
$205,697
|
Thomas J. Lynch(4)
|
|
|
|
$43,058
|
|
|
|
|
|
|
|
$80,550
|
|
|
|
|
|
|
|
|
|
$123,608
|
Peter J. Manning
|
|
|
|
$80,000
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
$8,025
|
|
|
$213,058
|
Jim P. Manzi
|
|
|
|
$250,000
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
$10,000
|
|
|
$385,033
|
William G. Parrett
|
|
|
|
$90,000
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
$10,000
|
|
|
$225,033
|
Michael E. Porter
|
|
|
|
$80,000
|
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$205,033
|
Scott M. Sperling(5)
|
|
|
|
$74,750
|
(6)
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$199,783
|
Elaine S. Ullian
|
|
|
|
$85,445
|
(7)
|
|
|
$125,033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$210,478
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) These amounts represent the
aggregate grant date fair value of stock awards and stock
options granted to directors in 2009, calculated in accordance
with the Companys financial reporting practices. For
information on the valuation assumptions with respect to these
awards, refer to note 5 of the Thermo Fisher financial
statements in the
Form 10-K
for the year ended December 31, 2009, as filed with the
SEC. These amounts do not represent the actual amounts paid to
or realized by the directors for these awards during fiscal year
2009. In May 2009, each non-management director on the Board at
that time received a grant of 3,540 fully vested shares, having
a grant date fair value of $125,033, all of which is included in
the stock awards column.
The following table shows, for each of our non-employee
directors, information concerning stock option awards granted
during their respective service periods in fiscal 2009 and the
corresponding grant date fair value of those awards, as well as
the aggregate number of stock option awards outstanding as of
December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Date Fair Value of
|
|
|
|
Aggregate Stock Option
|
|
|
|
|
Number of Stock Options
|
|
|
|
Stock Options Granted
|
|
|
|
Awards Outstanding as
|
|
Name
|
|
|
Granted in 2009
|
|
|
|
in 2009
|
|
|
|
of 12/31/09
|
|
Michael A. Bell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
Tyler Jacks
|
|
|
|
15,000
|
|
|
|
$
|
80,550
|
|
|
|
|
15,000
|
|
Stephen P. Kaufman
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
Judy C. Lewent
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
Thomas J. Lynch
|
|
|
|
15,000
|
|
|
|
$
|
80,550
|
|
|
|
|
15,000
|
|
Peter J. Manning
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,100
|
|
Jim P. Manzi
|
|
|
|
|
|
|
|
|
|
|
|
|
|
255,600
|
|
William G. Parrett
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
Michael E. Porter
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48,600
|
|
Scott M. Sperling
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,600
|
|
Elaine S. Ullian
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 45
(2) Represents matching company
contributions under the Matching Charitable Donation Program for
Directors.
(3) Includes compensation in the
amount of $35,000 deferred and issued as 904 deferred stock
units, pursuant to the Directors Deferred Compensation Plan.
(4) Elected to the Board in 2009.
(5) Does not include amounts paid
to Mr. Sperling under the Fisher Retirement Plan for
Non-Employee Directors because such amounts relate solely to
Mr. Sperlings service as a director of Fisher prior
to the Fisher Merger.
(6) Includes compensation in the
amount of $74,750 deferred and issued as 1,911 deferred stock
units, pursuant to the Directors Deferred Compensation Plan.
(7) Includes compensation in the
amount of $85,445 deferred and issued as 2,158 deferred stock
units, pursuant to the Directors Deferred Compensation Plan.
Stock
Ownership Policy for Directors
The Compensation Committee has established a stock holding
policy for directors of the Company. The stock holding policy
requires each director to hold shares of Common Stock equal in
value to at least three times the annual cash retainer for
directors. Directors who joined the Board after
February 25, 2005 have a period of five years from the date
of initial election to achieve this ownership level. For the
purpose of this policy, a directors election to receive
shares of Common Stock in lieu of director retainers and fees
(if applicable) will be counted towards this target. All of our
directors are either currently in compliance or intend to be in
compliance with this policy within the applicable time limit.
Executive officers of the Company are required to comply with a
separate stock holding policy established by the Compensation
Committee, which is described under the
sub-heading
Stock Ownership Policy under the heading
Compensation Discussion and Analysis.
Page 46
SECURITY
OWNERSHIP
Security
Ownership of Certain Beneficial Owners and Management
The following table sets forth, as of February 12, 2010,
the beneficial ownership of Common Stock by (a) each
director and nominee for director, (b) each of the
Companys executive officers named in the summary
compensation table set forth under the heading EXECUTIVE
COMPENSATION (the named executive officers),
(c) all directors and current executive officers as a
group, and (d) persons known to the Company to be the
beneficial owner of more than five percent of the Companys
Common Stock.
|
|
|
|
|
|
|
|
|
|
|
Amount and Nature of Beneficial
|
|
|
Percent of
|
|
Name and Address of Beneficial Owner(1)
|
|
Ownership
|
|
|
Shares Beneficially Owned
|
|
|
BlackRock, Inc.
|
|
|
27,878,601
|
(2)
|
|
|
6.81
|
%
|
Michael A. Bell
|
|
|
15,843
|
(3)
|
|
|
*
|
|
Marc N. Casper
|
|
|
500,740
|
(4)
|
|
|
*
|
|
Marijn E. Dekkers
|
|
|
0
|
|
|
|
*
|
|
Gregory J. Herrema
|
|
|
249,352
|
(5)
|
|
|
*
|
|
Tyler Jacks
|
|
|
1,100
|
|
|
|
*
|
|
Stephen P. Kaufman
|
|
|
16,683
|
(6)
|
|
|
*
|
|
Judy C. Lewent
|
|
|
8,540
|
(7)
|
|
|
*
|
|
Thomas J. Lynch
|
|
|
0
|
|
|
|
*
|
|
Alan J. Malus
|
|
|
248,164
|
(8)
|
|
|
*
|
|
Peter J. Manning
|
|
|
49,240
|
(9)
|
|
|
*
|
|
Jim P. Manzi
|
|
|
277,433
|
(10)
|
|
|
*
|
|
William G. Parrett
|
|
|
10,540
|
(11)
|
|
|
*
|
|
Edward A. Pesicka
|
|
|
291,682
|
(12)
|
|
|
*
|
|
Michael E. Porter
|
|
|
58,783
|
(13)
|
|
|
*
|
|
Scott M. Sperling
|
|
|
98,969
|
(14)
|
|
|
*
|
|
Elaine S. Ullian
|
|
|
59,800
|
(15)
|
|
|
*
|
|
Peter M. Wilver
|
|
|
256,034
|
(16)
|
|
|
*
|
|
All current directors and executive officers as a group
(21 persons)
|
|
|
2,882,388
|
(17)
|
|
|
*
|
|
* Less than one percent.
(1) The address of each of the
Companys executive officers and directors is
c/o Thermo
Fisher Scientific Inc., 81 Wyman Street, Waltham, MA 02451.
Except as reflected in the footnotes to this table, shares of
Common Stock beneficially owned by executive officers and
directors consist of shares owned by the indicated person or by
that person for the benefit of minor children, and all share
ownership includes sole voting and investment power. Generally,
stock options granted to the Companys officers and
directors may be transferred by them to an immediate family
member, a family trust or family partnership.
(2) This information was obtained
from Schedule 13G filed with the Securities and Exchange
Commission on January 29, 2010, by BlackRock, Inc., 40 East
52nd Street, New York, NY 10022, which reported such ownership
as of December 31, 2009. The percentage of shares
beneficially owned was calculated using the number of shares of
Common Stock outstanding as of February 12, 2010.
(3) Includes 160 shares held
indirectly by the Michael A. Bell 1992 Trust and
10,000 shares of Common Stock underlying stock options that
are exercisable within 60 days of February 12, 2010.
(4) Includes 416,140 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010. Also includes
14,169 shares of restricted Common Stock which may be voted
by Mr. Casper, but may not be sold or transferred until
future vesting dates.
Page 47
(5) Includes 219,593 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010, and 11,657
restricted stock units that will vest within 60 days of
February 12, 2010. Also includes 4,977 shares of
restricted Common Stock which may be voted by Mr. Herrema,
but may not be sold or transferred until future vesting dates.
(6) Includes 10,000 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(7) Includes 5,000 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(8) Includes 166,080 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010 and 11,657
restricted stock units that will vest within 60 days of
February 12, 2010. Also includes 10,123 shares of
restricted Common Stock which may be voted by Mr. Malus,
but may not be sold or transferred until future vesting dates.
(9) Includes 41,100 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(10) Includes 255,600 shares
of Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(11) Includes 5,000 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(12) Includes 231,693 shares
of Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010, and 11,657
restricted stock units that will vest within 60 days of
February 12, 2010. Also includes 4,821 shares of
restricted Common Stock which may be voted by Mr. Pesicka,
but may not be sold or transferred until future vesting dates.
(13) Includes 48,600 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(14) Includes 75,600 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(15) Includes 48,600 shares of
Common Stock underlying stock options that are exercisable
within 60 days of February 12, 2010.
(16) Includes 14,728 shares
held indirectly by the Peter M. Wilver 2009 Qualified Annuity
Interest Trust, 210,960 shares of Common Stock underlying
stock options that are exercisable within 60 days of
February 12, 2010, and 10,103 restricted stock units that
will vest within 60 days of February 12, 2010. Also
includes 9,688 shares of restricted Common Stock which may
be voted by Mr. Wilver, but may not be sold or transferred
until future vesting dates.
(17) Includes, in addition to the
items described above for the current named executive officers
and directors, 941 shares held in the Companys 401(k)
Plan by executive officers other than the named executive
officers, 546,513 shares of Common Stock underlying stock
options held by executive officers other than the named
executive officers that are exercisable within 60 days of
February 12, 2010, 45,940 shares of restricted Common
Stock and restricted stock units held by executive officers
other than the named executive officers that will vest within
60 days of February 12, 2010 (or immediately if
certain eligible executive officers retire), and
3,006 shares of restricted Common Stock beneficially owned
by executive officers other than the named executive officers,
which may be voted, but may not be sold or transferred until
future vesting dates.
Section 16(a)
Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as
amended (the Exchange Act), requires the
Companys directors and executive officers, and beneficial
owners of more than 10% of the Common Stock, to file with the
Securities and Exchange Commission initial reports of ownership
and periodic reports of changes
Page 48
in ownership of the Companys securities. Based upon a
review of such filings, all Section 16(a) filing
requirements applicable to such persons were complied with
during 2009, except that in March 2010, the Company filed a late
Form 4 with respect to 13 shares purchased by
Mr. Bell in September 2009.
TRANSACTIONS
WITH RELATED PERSONS, PROMOTERS AND CERTAIN CONTROL
PERSONS
Review,
Approval or Ratification of Transactions with Related
Persons
Our Board has adopted written policies and procedures for the
review of any transaction, arrangement or relationship in which
the Company is a participant, the amount involved exceeds
$120,000, and one of our executive officers, directors, director
nominees or 5% stockholders (or their immediate family members),
each of whom we refer to as a related person, has a
direct or indirect material interest.
If a related person proposes to enter into such a transaction,
arrangement or relationship, which we refer to as a
related person transaction, the related person must
report the proposed related person transaction to our General
Counsel. The policy calls for the proposed related person
transaction to be directed to, for review by, one of the Audit,
Nominating and Corporate Governance or Compensation Committees,
as designated by the General Counsel. Whenever practicable, the
reporting, review and approval will occur prior to entry into
the transaction. If advance review and approval is not
practicable, the committee will review, and, in its discretion,
may ratify the related person transaction. The policy also
permits the chairman of the committee to review and, if deemed
appropriate, approve proposed related person transactions that
arise between committee meetings, subject to ratification by the
committee at its next meeting. A related person transaction
reviewed under the policy will be considered approved or
ratified if it is authorized by the committee after full
disclosure of the related persons interest in the
transaction. As appropriate for the circumstances, the committee
will review and consider:
the related
persons interest in the related person transaction;
|
|
|
|
|
the approximate dollar value of the amount involved in the
related person transaction;
|
the approximate
dollar value of the amount of the related persons interest
in the transaction without regard to the amount of any profit or
loss;
|
|
|
|
|
whether the transaction was undertaken in the ordinary course of
our business;
|
whether the terms of
the transaction are no less favorable to the Company than terms
that could have been reached with an unrelated third party;
|
|
|
|
|
the purpose of, and the potential benefits to the Company of,
the transaction; and
|
any other information
regarding the related person transaction or the related person
in the context of the proposed transaction that would be
material to investors in light of the circumstances of the
particular transaction.
The committee may approve or ratify the transaction only if the
committee determines that, under all of the circumstances, the
transaction is in, or is not inconsistent with, the
Companys best interests. The committee may impose any
conditions on the related person transaction that it deems
appropriate.
The policy exempts from the definition of related person
transactions those transactions that are excluded by the
instructions to the SECs related person transaction
disclosure rule, as well as the following: interests arising
solely from the related persons position as an executive
officer of another entity (whether or not the person is also a
director of such entity), that is a participant in the
transaction, where (a) the related person and all other
related persons own in the aggregate less than a 10% equity
interest in such entity, (b) the related person and his or
her immediate family members are not involved in the negotiation
of the terms of the transaction and do not receive any special
benefits as a result of the transaction, (c) the amount
involved in the transaction equals less than the greater of
$1 million dollars or 2% of the annual consolidated gross
revenues
Page 49
of the other entity that is a party to the transaction, and
(d) the amount involved in the transaction equals less than
2% of the Companys annual consolidated gross revenues.
The policy provides that transactions involving compensation of
executive officers shall be reviewed and approved by the
Compensation Committee in the manner specified in its charter.
Transactions
with Related Persons
Michael Bell was elected to the Board on July 12, 2007.
Mr. Bell is a Managing Director of Monitor Clipper
Partners, a private equity investment firm based in Cambridge,
Massachusetts. Monitor Clipper Partners currently manages over
$1.5 billion of capital.
The Fisher Scientific International Inc. Defined Benefit Master
Trust (the Fisher Defined Benefit Plan or the
DB Plan) has invested in two funds managed by
Monitor Clipper Partners. The commitment for these investments
was made prior to the Fisher Merger. The Fisher Defined Benefit
Plan made a capital commitment of $2,500,000 to the first fund
(Fund I) in 1997 and has contributed $2,474,695
to Fund I. Fund I has returned $2,952,123 to the DB
Plan through December 31, 2009, leaving remaining capital
of $374,517. The DB Plans interests represent less than
0.5% of the partnership interests in Fund I.
The Fisher Defined Benefit Plan made a capital commitment of
$2,100,000 to the second fund (Fund II) in
2003, and has contributed $2,055,206 to Fund II.
Fund II has returned $567,802 to the DB Plan through
December 31, 2009, leaving remaining capital of $1,175,040.
The DB Plans interests represent less than 0.3% of the
partnership interests in Fund II. As of December 31,
2009, the DB Plans investments in Fund I and
Fund II (the Funds) represented less than 1% of
the DB Plans total assets.
Monitor Clipper Partners collects from the Funds an annual
management fee of approximately 2% of assets and receives a
carried interest of approximately 20% in the performance of the
Funds. Through his position as Managing Director of Monitor
Clipper Partners and his ownership interest in the firm,
Mr. Bell indirectly shares in the compensation paid by the
Funds to Monitor Clipper Partners. These arrangements were not
subject to the Companys related person transaction policy
described above because they were entered into by Fisher prior
to the Fisher Merger.
EQUITY
COMPENSATION PLAN INFORMATION
The following table provides information as of December 31,
2009, with respect to the Common Stock that may be issued under
the Companys existing equity compensation plans.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
|
|
(a)
|
|
|
|
(b)
|
|
|
Number of securities remaining
|
|
|
|
|
Number of securities to
|
|
|
|
Weighted average
|
|
|
available for future issuance
|
|
|
|
|
be issued upon exercise
|
|
|
|
exercise price of
|
|
|
under equity compensation
|
|
|
|
|
of outstanding options,
|
|
|
|
outstanding options,
|
|
|
plans (excluding securities
|
|
Plan Category
|
|
|
warrants and rights(1)
|
|
|
|
warrants and rights
|
|
|
reflected in column (a))(2)
|
|
Equity Compensation
Plans Approved By
Security Holders(3)(4)(5)(6)
|
|
|
|
14,571,767
|
|
|
|
$40.47
|
|
|
|
23,745,118
|
|
Equity Compensation
Plans Not Approved By
Security Holders(7)
|
|
|
|
5,880,216
|
|
|
|
$41.32
|
|
|
|
1,679,354
|
|
Total
|
|
|
|
20,451,983
|
|
|
|
$40.74
|
|
|
|
25,424,472
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) This table excludes options to
purchase shares of the Companys formerly majority-owned
subsidiaries which became options to purchase shares of the
Company when the outside interests in those subsidiaries were
repurchased by the Company during 1999 through 2002, and options
to purchase shares of Fisher, which became options to purchase
shares of the Company when the Company acquired Fisher in
November 2006. All of the plans pursuant to which these options
were granted have been frozen and no additional grants will
Page 50
be made. Options to purchase an aggregate of
1,577,828 shares at a weighted average exercise price of
$23.74 per share are outstanding under these plans.
(2) Equity compensation plans
approved by security holders includes 7,800,667 securities
available for future issuance as awards other than options or
stock appreciation rights (e.g., full value shares of restricted
stock or restricted stock units) and equity compensation plans
not approved by security holders includes 964,122 securities
available for future issuance as awards other than options or
stock appreciation rights.
(3) Column (a) includes an
aggregate of 13,836 Common Stock-based units accrued under the
Directors Deferred Compensation Plan for deferred
directors fees and retainers accrued through
December 31, 2009. Column (c) includes an additional
286,262 shares that are available under the Directors
Deferred Compensation Plan. See DIRECTOR
COMPENSATION Deferred Compensation Plans for
Directors for additional information regarding this plan.
The weighted average exercise price set forth in column
(b) does not take into account the Common Stock-based units
included in column (a).
(4) Column (a) includes an
aggregate of 783,579 Common Stock time-based restricted stock
units outstanding granted under the Companys approved
plans and 189,454 Common Stock time-based restricted stock units
outstanding granted under unapproved plans. The weighted average
exercise price set forth in column (b) does not take into
account the Common Stock time-based units included in column (a).
(5) Column (a) includes an
aggregate of 1,196,000 Common Stock performance-based restricted
stock units outstanding under the Thermo Fisher Scientific Inc.
2008 Stock Incentive Plan. The weighted average exercise price
set forth in column (b) does not take into account the
Common Stock performance-based units included in column (a).
(6) Column (a) does not
include shares issuable under the Thermo Fisher Scientific Inc.
2007 Employees Stock Purchase Plan (the ESPP),
which has a remaining stockholder approved reserve of
1,900,149 shares. Under the ESPP, each eligible employee
may purchase a limited number of shares of the Common Stock of
the Company two times each year (on June 30 and December
31) at a purchase price equal to 95% of the fair market
value of the Common Stock on the respective stock purchase date.
The remaining stockholder approved reserve is included in column
(c).
(7) Equity compensation plans not
approved by the Companys stockholders are (i) the
Thermo Fisher Scientific Inc. Employees Equity Incentive Plan,
as amended and restated on November 9, 2006, under which
70,082 shares are available for future issuance, and
(ii) the Fisher Scientific International Inc. 2005 Equity
and Incentive Plan, as amended for awards granted on or after
November 9, 2006 (the Fisher 2005 Plan), under
which 1,609,272 shares are available for future issuance.
In connection with the Fisher Merger, the Company assumed
options to purchase stock under the Fisher 2005 Plan. At
December 31, 2009, these options covered
910,956 shares of Common Stock at a weighted average
exercise price of $32.23. Prior to the Fisher Merger, the Fisher
2005 Plan was approved by the Fisher stockholders. The material
terms of these plans are described below.
Thermo
Fisher Scientific Inc. Employees Equity Incentive Plan
The Thermo Fisher Scientific Inc. Employees Equity Incentive
Plan, as amended and restated on November 9, 2006 (the
Employees Equity Plan), was adopted to secure for
the Company and its stockholders the benefits arising from
capital stock ownership by employees of and consultants to the
Company. The Employees Equity Plan is administered by the
Companys Board (or a committee thereof), which has the
full authority, among other things, to (i) select the
persons to whom awards will be granted, (ii) determine the
terms and conditions of the awards, and (iii) amend or
terminate the plan. Under the Employees Equity Plan,
3,488,867 shares were originally reserved for issuance; as
of December 31, 2009, 70,082 shares are available for
future issuance under the plan. Participants may receive
non-statutory stock options, restricted stock awards, deferred
stock awards (also known as restricted stock units) and
performance awards (which may consist of stock
and/or
cash). The exercise price of stock options granted may not be
less than the fair market value of the Companys shares on
the date of the grant.
Page 51
Fisher
Scientific International Inc. 2005 Equity and Incentive
Plan
The Fisher 2005 Plan was originally adopted to secure for Fisher
and its stockholders the benefits arising from capital stock
ownership by employees of and consultants to the Company. The
Fisher 2005 Plan is administered by the Companys Board (or
a committee thereof), which has the full authority, among other
things, to (i) select the persons to whom awards will be
granted, (ii) determine the terms and conditions of the
awards, and (iii) amend or terminate the plan. Under the
Fisher 2005 Plan, 7,250,000 shares were originally reserved
for issuance (14,500,000 on a post-merger basis); as of
December 31, 2009, 1,609,272 shares are available for
future issuance under the plan. Participants may receive
non-statutory stock options, restricted stock awards, deferred
stock awards (also known as restricted stock units) and
performance awards (which may consist of stock
and/or
cash). The exercise price of stock options granted may not be
less than the fair market value of the Companys shares on
the date of the grant.
Page 52
REPORT OF
THE AUDIT COMMITTEE
The Audit Committee is responsible for assisting the Board in
its oversight of the integrity of the Companys financial
statements, the Companys compliance with legal and
regulatory requirements, the independent auditors
qualifications and independence, and the performance of the
Companys internal audit function and independent auditors.
The full text of the Audit Committees charter is available
on the Companys website at www.thermofisher.com.
As specified in the charter, management of the Company is
responsible for the preparation, presentation, and integrity of
the Companys financial statements and for the
appropriateness of the accounting principles and reporting
policies that are used by the Company. The independent auditors
are responsible for auditing the Companys financial
statements and for reviewing the Companys unaudited
interim financial statements. The authority and responsibilities
of the Audit Committee set forth in its charter do not reflect
or create any duty or obligation of the Audit Committee to plan
or conduct any audit, to determine or certify that the
Companys financial statements are complete, accurate,
fairly presented, or in accordance with generally accepted
accounting principles or applicable law, or to guarantee the
independent auditors report.
In fulfilling its oversight responsibilities, the Audit
Committee has reviewed and discussed the audited financial
statements of the Company for the fiscal year ended
December 31, 2009, managements assessment of the
effectiveness of the Companys internal control over
financial reporting and the independent auditors audit of
the Companys internal control over financial reporting
with management and the Companys independent auditors,
PricewaterhouseCoopers LLP (PwC).
The Audit Committee has also discussed with PwC the matters
required to be discussed by the Statement on Auditing Standards
No. 61, as amended (AICPA, Professional Standards,
Vol. 1, AU section 380), as adopted by the Public Company
Accounting Oversight Board, as currently in effect. The Audit
Committee has received from PwC the letter and written
disclosures required by applicable requirements of the Public
Company Accounting Oversight Board, as currently in effect,
regarding the independent auditors communications with the
Audit Committee concerning independence, and has discussed with
PwC the auditors independence.
Based upon the review and discussions described in this report,
the Audit Committee recommended to the Board that the audited
financial statements be included in the Companys Annual
Report on
Form 10-K
for the year ended December 31, 2009, filed with the SEC.
THE AUDIT COMMITTEE
William G. Parrett (Chairman)
Thomas J. Lynch
Peter J. Manning
Page 53
INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
Independent
Auditor Fees
The following table presents the aggregate fees billed for
professional services rendered by PwC for the fiscal years ended
December 31, 2009, and December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
Fiscal 2009
|
|
|
Fiscal 2008
|
|
|
Audit Fees
|
|
|
$11,914,000
|
(1)
|
|
|
$12,533,000
|
|
Audit-Related Fees
|
|
|
$587,000
|
|
|
|
$230,000
|
|
Tax Fees
|
|
|
$4,453,000
|
(2)
|
|
|
$4,997,000
|
(2)
|
All Other Fees
|
|
|
|
|
|
|
|
|
Total Fees
|
|
|
$16,954,000
|
|
|
|
$17,760,000
|
|
(1) Reflects aggregate audit fees
billed/estimated to be billed for professional services rendered
by PwC for 2009.
(2) Represents tax consulting
services.
Audit
Fees
Consists of fees billed/estimated to be billed for professional
services rendered by PwC for the audit of the Companys
annual consolidated financial statements (including PwCs
assessment of the Companys internal control over financial
reporting) and review of the Companys interim financial
statements included in the Companys quarterly reports on
Form 10-Q
and services that are normally provided by PwC in connection
with statutory and regulatory filings or engagements for those
fiscal years.
Audit-Related
Fees
Consists of fees billed for assurance and related services by
PwC that are reasonably related to the performance of the audit
or review of the Companys consolidated financial
statements and are not reported under Audit Fees
above. These services include employee benefit plan audits,
accounting consultations relating to acquisitions, divestitures,
and financings, financial accounting and reporting matters,
internal controls review and SEC filing related matters.
Tax
Fees
Consists of fees billed for professional services rendered by
PwC for tax compliance, tax advice, and tax planning. These
services include professional services related to the
Companys international legal entity restructuring and
international and domestic tax planning.
All Other
Fees
Consists of fees billed for all other services provided by PwC
other than those reported above, of which there were none in
fiscal years 2009 and 2008.
Audit
Committees Pre-Approval Policies and Procedures
The Audit Committees charter provides that the Audit
Committee must pre-approve all audit services and non-audit
services to be provided to the Company by its independent
auditor as well as all audit services to be provided to the
Company by other accounting firms. However, the charter permits
de minimis non-audit services to be provided to the Company by
its independent auditors to instead be approved in accordance
with the listing standards of the NYSE and SEC rules and
regulations. In addition, the charter provides that the Audit
Committee may delegate to one or more members of the Audit
Committee the authority to grant pre-approvals of permitted
non-audit services that would otherwise be required to be
pre-approved by the Audit Committee. Any pre-approvals granted
under such delegation of authority are to be reported to the
Audit Committee at the next regularly scheduled meeting. The
Audit Committee has delegated authority to the
Page 54
chairman of the Audit Committee to pre-approve up to an
additional $100,000 of permitted non-audit services to be
provided to the Company by its independent auditors per calendar
year. During fiscal years 2009 and 2008, all audit services and
all non-audit services provided to the Company by PwC were
pre-approved in accordance with the Audit Committees
pre-approval policies and procedures described above and no
services were provided pursuant to the de minimis exception.
-PROPOSAL 2-
RATIFICATION
OF SELECTION OF INDEPENDENT AUDITORS
The Audit Committee has selected PricewaterhouseCoopers LLP as
the Companys independent auditors for the fiscal year
ending December 31, 2010. During the 2009 fiscal year, PwC
served as the Companys independent auditors. See
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
Although the Company is not required to seek stockholder
ratification of this selection, the Company has decided to
provide its stockholders with the opportunity to do so. If this
proposal is not approved by our stockholders at the 2010 Annual
Meeting of Stockholders, the Audit Committee will reconsider the
selection of PwC. Even if the selection of PwC is ratified, the
Audit Committee in its discretion may select a different firm of
independent auditors at any time during the year if it
determines that such a change would be in the best interest of
the Company and its stockholders.
Representatives of PwC are expected to be present at the 2010
Annual Meeting of Stockholders. They will have the opportunity
to make a statement if they desire to do so and will be
available to respond to appropriate questions from the
stockholders.
The Board of Directors recommends a vote FOR the
ratification of the selection of PricewaterhouseCoopers LLP as
the Companys independent auditors for fiscal year
2010. Proxies solicited by the Board will be voted FOR the
proposal unless stockholders specify to the contrary on their
proxy.
OTHER
ACTION
Management is not aware at this time of any other matters that
will be presented for action at the 2010 Annual Meeting of
Stockholders, and the deadline under our bylaws for stockholders
to notify the Company of any proposals or director nominees has
passed. Should any other matters be properly presented, the
proxies grant power to the proxy holders to vote shares
represented by the proxies in the discretion of such proxy
holders.
STOCKHOLDER
PROPOSALS
Proposals of stockholders intended to be included in the proxy
statement and proxy card relating to the 2011 Annual Meeting of
Stockholders of the Company and to be presented at such meeting
must be received by the Company for inclusion in the proxy
statement and proxy card no later than December 9, 2010. In
addition, the Companys bylaws include an advance notice
provision that requires stockholders desiring to bring proposals
before an annual meeting (which proposals are not to be included
in the Companys proxy statement and thus are submitted
outside the processes of
Rule 14a-8
under the Exchange Act) to do so in accordance with the terms of
such advance notice provision. The advance notice provision
requires that, among other things, stockholders give timely
written notice to the Secretary of the Company regarding their
proposals. To be timely, notices must be delivered to the
Secretary at the principal executive office of the Company not
less than 60, nor more than 75, days prior to the first
anniversary of the date on which the Company mailed its proxy
materials for the preceding years annual meeting of
stockholders. Accordingly, a stockholder who intends to present
a proposal at the 2011 Annual Meeting of Stockholders without
inclusion of the proposal in the Companys proxy materials
must provide written notice of such proposal to the Secretary no
earlier than January 23, 2011, and no later than
February 7, 2011. Proposals received at any other time will
not be voted on at the meeting. If a stockholder makes a timely
notification, the proxies that management
Page 55
solicits for the meeting may still exercise discretionary voting
authority with respect to the stockholders proposal under
circumstances consistent with the proxy rules of the SEC.
SOLICITATION
STATEMENT
The cost of this solicitation of proxies will be borne by the
Company. Solicitation will be made primarily by mail, but
regular employees of the Company may solicit proxies personally
or by telephone, facsimile transmission or telegram. In
addition, the Company has engaged The Altman Group, Inc. in
order to assist in the solicitation of proxies and will
reimburse The Altman Group for its reasonable costs and
expenses. Brokers, nominees, custodians and fiduciaries are
requested to forward solicitation materials to obtain voting
instructions from beneficial owners of stock registered in their
names, and the Company will reimburse such parties for their
reasonable charges and expenses in connection therewith.
HOUSEHOLDING
OF ANNUAL MEETING MATERIALS
Some banks, brokers and other nominee record holders may be
participating in the practice of householding proxy
statements, notices of internet availability of proxy materials
and annual reports. This means that only one copy of our proxy
statement, notice of internet availability of proxy materials
and annual report to stockholders may have been sent to multiple
stockholders in your household. The Company will promptly
deliver a separate copy of any of these documents to you if you
contact us at the following address or telephone number:
Investor Relations Department, Thermo Fisher Scientific Inc., 81
Wyman Street, Waltham, Massachusetts 02451, telephone:
781-622-1111.
If you want to receive separate copies of the proxy statement,
notice of internet availability of proxy materials or annual
report to stockholders in the future, or if you are receiving
multiple copies and would like to receive only one copy per
household, you should contact your bank, broker, or other
nominee record holder, or you may contact the Company at the
above address or telephone number.
Waltham, Massachusetts
April 8, 2010
THERMO FISHER SCIENTIFIC INC.
81 WYMAN STREET
WALTHAM, MA 02451
VOTE BY INTERNET - www.proxyvote.com
Use the Internet to transmit your voting instructions and for electronic delivery
of information up until 11:59 P.M. Eastern Time the
day before the cut-off date or meeting date. Have your proxy
card in hand when you access the web site and follow the instructions to obtain
your records and to create an electronic voting instruction form.
ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS
If you would like to reduce the costs incurred by our company in
mailing proxy materials, you can consent to receiving all future proxy
statements, proxy cards and annual reports electronically via e-mail
or the Internet. To sign up for electronic delivery, please follow the
instructions above to vote using the Internet and, when prompted, indicate
that you agree to receive or access proxy materials electronically in future years.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the
day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow
the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope
we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717.
|
|
|
|
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
|
|
|
|
|
|
|
|
M23207-P93437-Z52400 |
|
KEEP THIS PORTION FOR YOUR RECORDS |
|
|
|
|
|
DETACH AND RETURN THIS PORTION ONLY |
THIS PROXY CARD IS VALID ONLY WHEN
SIGNED AND DATED.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THERMO FISHER SCIENTIFIC INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Board of Directors recommends you vote FOR
each of the following nominees. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. |
Election of Directors |
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain |
|
|
|
|
Nominees: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1a.
|
|
Marc N. Casper
|
|
o
|
|
o
|
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1b.
|
|
Tyler Jacks
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
The Board of Directors recommends you vote FOR the following proposal. |
|
For |
|
Against |
|
Abstain |
|
|
|
|
|
|
|
|
|
|
|
2. |
|
Ratification of the Audit Committees selection
of PricewaterhouseCoopers LLP as the Companys independent auditors for 2010.
|
|
o |
|
o |
|
|
o |
|
|
|
|
3. |
|
Such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For address change/comments,
mark here. (see reverse side for instructions)
|
|
|
|
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
Please indicate if you plan to attend this meeting.
|
|
|
o
Yes |
|
|
|
o
No |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Please sign exactly as your name(s) appear(s) hereon. When signing
as attorney, executor, administrator, or other fiduciary,
please give full title as such. Joint owners should each sign personally.
All holders must sign. If a corporation or partnership, please sign in full
corporate or partnership name, by authorized officer. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature [PLEASE SIGN WITHIN BOX]
|
|
Date |
|
Signature (Joint Owners) |
|
Date |
|
|
Important Notice Regarding the Availability of
Proxy Materials for the Annual Meeting:
The Annual Report and Notice and Proxy Statement are available at www.proxyvote.com.
M23208-P93437-Z52400
THERMO FISHER SCIENTIFIC INC.
This proxy is solicited by the Board of Directors
ANNUAL MEETING OF THE STOCKHOLDERS TO BE
HELD ON MAY 26, 2010
The stockholder(s) hereby appoint(s) Marc N. Casper, Jim P. Manzi
and Peter M. Wilver, as proxies, each with power to appoint his substitute, and
hereby authorize(s) them to represent and to vote, as designated on the reverse
side of this proxy card, all the shares of Common Stock of Thermo Fisher Scientific Inc.
that the stockholder(s) is/are entitled to vote at the Annual Meeting of the Stockholders
to be held at the Mandarin Oriental New York, 80 Columbus Circle at 60th Street, New
York, New York 10023, on Wednesday, May 26, 2010, at 1:30 p.m., and at any adjournments
or postponement thereof.
The Proxy will be voted as specified, or if no choice is specified,
FOR the election of each of the
nominees for director,
FOR ratification of selection of the independent auditors
and as said
proxies deem advisable on such other matters as may properly come before the meeting.
(If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)
Continued and to be signed on reverse side